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Abstract
Paper-Based Point-of-Care Tools for Blood Testing
Xuefei Gao
Early detection of malignant disease is crucial for timely diagnosis and effective medical
intervention, which significantly increases survival rates and reduce financial burden on patients.
Biomarkers are becoming increasingly important in detection of malignant diseases, because
they can be employed for indicating diseases, predicting risks and monitoring the progression of
diseases. In addition, biomarkers show up at early stages of diseases in human tissues and fluids
(e.g., blood, urine and saliva), which shows great promise for early disease detection. In this
dissertation, paper-based lateral flow strips (PLFSs) have been developed for the detection of
disease biomarkers, including protein biomarkers and microRNA (miRNA) biomarkers from
clinical samples and whole blood samples. Among most of the reported biosensors, PLFSs
appear to be an effective tool for providing access to point-of-care (POC) applications, due to
low cost, fast response, portability and ease of use. In addition, paper is compatible with
biological samples, which allows its application in analyzing various biomolecules. However,
conventional PLFSs exhibit insufficient sensitivity and poor interference resistance. In particular
whole blood samples, which contain numerous interference biomolecules, substantially affect
detection accuracy and specificity.
In this dissertation, several strategies have been employed to solve the problems, including
introducing PLFSs with ultrasensitive techniques, meanwhile modifying PLFSs with functional
nanomaterials and paper accessory unit to reduce the interference biomolecules from human
fluids. In summary, five chapters will be demonstrated:
(1) Surface-enhanced Raman scattering (SERS) technique modified PLFSs for protein
biomarker detection in clinical blood plasma samples. In this chapter, silica coated SERS
nanoparticles (NPs) have been developed for improving Raman signal and detection sensitivity,
at the same time, silica coating of the SERS NPs substantially improve the stability of the NPs in
complex human fluids. As a result, the developed SERS-PLFS can realize direct detection of
neuron-specific enolase (NSE) from clinical blood plasma samples of traumatic brain injury
(TBI) patients. The test results of the SERS-PLFSs were compatible with those from the standard
enzyme-linked immunospecific assay (ELISA) method;
(2) Blood plasma separation unit (PSU) integrated PLFS for cancer protein biomarker
detection from whole human blood sample. In this chapter, a paper based PSU was fabricated to
efficiently retain red blood cells (RBCs) inside the unit to block their migration and meanwhile
push the target protein contained plasma to the detection area of the PLFS. As a result, cancer
protein biomarker-carcinoembryonic antigen (CEA) was successfully detected by the PSU-PLFS
from whole blood samples;
(3) Plasmonic chip and PSU integrated PLFS for protein biomarker detection from whole
blood. In order to meet the high sensitivity demand, a gold nanopyramid array functionalized
chip was integrated into a PLFS for amplifying Raman signal and ultrasensitive detection of TBI
protein biomarker s-100β; while the PSU was utilized to reduce the RBCs interference from

whole blood. As a result, compared with the result of the SERS-PLFS in Chapter 2, an
improvement in LOD with two-order of magnitude was obtained;
(4) Near-infrared fluorophores (NIRFs) functionalized PLFS for miRNA detection from blood
plasma. In this chapter, NIRFs encapsulated silica nanoparticles were synthesized and
incorporated into a PLFS for stroke biomarker miRNA-34 detection. Compared with a single
fluorescent dye, the synthesized NIRF NPs encapsulated numerous fluorophores into one single
silica nanoparticle, exhibiting amplified luminescent intensity. Moreover, the NIRF nanoparticles
minimized the fluorescent background from biological matrices and test strip materials, which
elevates signal-to-noise ratio and anti-interference capacity;
(5) Duplex specific nuclease (DSN) based signal amplification strategy modified PLFS for
ultrasensitive miRNA detection in blood plasma. In order to meet the high sensitivity demand of
miRNA-34 measurement from the clinical blood plasma of stroke patient, the developed NIRFsPLFS in Part 4 was further elevated with DSN modification for amplifying fluorescent signal. As
a result, the DSN-PLFS exhibited an improvement in detection sensitivity with two-orders of
magnitude in blood plasma.
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Chapter 1: INTRODUCTION
1.1 BACKGROUND AND MOTIVATION
A critical and challenging future direction in science and engineering is to develop
technologies to improve the health of people in the developing and remote regions of the world.1
However, advanced diagnostic technologies are always centralized and requiring sophisticated
instruments, specialized laboratory personnel and expensive chemicals. Moreover, continuous
and long term monitoring add tremendous time and financial burden on patients due to
soaring costs and frequent travel to hospitals and institutions. These factors have accelerated the
emphasis on the development of low-cost, easy-to-operated and reliable devices to shift
diagnostic testing from medical institutes and laboratories to the sites of patient care.
Diagnostic testing conducted at or near the patient’s bedside is called point-of-care testing
(POCT), which can be operated by patients themselves, caretaker or healthcare professionals
outside of the clinical laboratory. In addition, POCTs allow test results to be read out facilely and
quickly, which assists in making clinical management decisions in an immediate and timely
manner.2 There is an increasing need of POC diagnostics, the corresponding expenses are
projected to reach USD 38.13 Billion by 2022 from USD 23.71 Billion in 2017. Nowadays, the
most widely applied POC device is blood glucose test strip, which was proposed in 1962 and
bolstered by a portable pregnancy test strip in 1977.3 Since then, numerous paper-based lateral
flow strips (PLFSs) has been developed for drugs screening, food pathogens screening and
infectious disease testing. Most of the testing samples are human fluids, such as whole blood,
serum, plasma, saliva and urine, which are easy to be collected and can provide diverse sensing
pathways in a less-invasive mode. The underlying mechanism of a PLFS is based on sensing of a
target molecule or biomarker. For example, a pregnancy test strip is manufactured for detecting
human chorionic gonadotrophin (hCG) from urine sample, which is a protein biomarker relating
with the pregnancy progression.4 In a typical pregnancy test, the urine sample is firstly collected
into a container. And then the sample is moved from the container to the sample area of the
pregnancy test strip through a dropper. By capillary force, the specimen flows from the sample
area to the detection area. If hCG is present in the specimen, it will react with the conjugated
NPs, which binds to the hCG-antibody on the detection area to generate a colored band. Presence
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of two colored bands, which are respectively located at the detection area and control area,
indicating a positive result; while the absence of the band located at the detection area indicates a
negative result. The test procedure can be completed generally within 20 min. However, there are
tradeoffs. In order to simplifying and reducing the cost, the sensitivity and accuracy of a PLFS
are always sacrificed. As a result, most of the current PLFSs rarely deal with early-stage
biomarker detection, owing to the fact that early stage diseases always relate with trace amounts
of biomarkers. In addition, a relative large quantity of interference molecules existing in human
fluids decreases sensing specificity and reduce signal accuracy of the devices. Therefore, it is of
great significant to develop PLFSs with elevated performances to address the unmet need for
sensitive and reliable measurement of early-stage biomarker from human fluids.
1.2 OBJECTIVE
In this dissertation, the objective is to address the problems and develop a sensitive, portable
and low-cost sensor platform towards POC applications for early-stage biomarker detection in
human fluids. To meet the demands, the following objectives are of paramount importance:
1) The developed sensor should be portable, easy-operated and low-cost;
2) The proposed device should address the limitations of current PLFSs, in terms of
sensitivity, specificity and anti-interference ability;
3) The proposed sensor platform should show promises as a real POC tool for practical
applications.
1.3 SIGNIFICANCE
There is an increasing need of employing POC tools for early-stage disease monitoring.
However, most of the reported biosensors suffer from low sensitivity and poor anti-interference
capacity towards non-specific interference biomolecules in complex human fluids, which limit
their applications in early stage disease detection. Therefore, my research aims to fill the gaps
and overcome those challenges to fabricate viable and portable biosensors with high sensitivity
and anti-interference capability.
The proposed research is significant in that:
1) It demonstrates the limitations and gaps between the existing state-of-the-art biosensors
2

and the desired POC tools;
2) It proposes innovative approaches and sensing mechanisms to address the challenges of
PLFSs;
3) The proposed approaches and sensing mechanisms can be adapted to other applications,
exhibiting transformative potential of the work.
As a result, the developed PLFS in this dissertation enables direct disease biomarker detection
from clinical plasma samples and whole blood samples. In addition, the obtained data from the
developed PLFSs was comparable with that from the clinical standard ELISA method, exhibiting
great promises as potential POC tools for practical applications.
1.4 INNOVATION
Several innovative strategies have been proposed in this dissertation to address the issues
arose from current PLFSs, including:
1) Ultrasensitive detection was realized through employment of surface-enhanced Raman
scattering (SERS) technique and fluorescent technique into PLFS;
2) The interference from non-specific biomolecules from human fluids was reduced by tuning
optical property of nanomaterials to the biological transparent window;
3) The anti-interference ability of the functional nanomaterials was improved through coating
nanomaterials with silica layers, which can serve as a barrier to NPs from the interference
biomolecules in human fluids;
4) The interference of red blood cells (RBCs) from whole blood was reduced via modifying
PLFS with plasma separation unit (PSU); the separation efficiency and separation rate was
substantially elevated through employing functional chemicals;
6) Signal amplification strategy of nuclease modification was introduced into PLFS for
improving signal intensity and sensitivity.
The reason for choosing SERS technique and fluorescent technique to modify PLFS is owing
to the fact that they can offer LFTS with substantially elevated signal intensity and detection
sensitivity. Moreover, compared with SERS technique, fluorescent technique exhibits an
additional advantage in simplicity during signal acquisition.

3

1.5 OPERATION PRINCIPLE OF TEST STRIP
PLFSs have been developed for analyzing target analytes within particular fluids beginning in
the late 1970s with the advantages of simplicity, low cost, portability and instantaneous diagnosis
in the proximity of the patients. After that, PLFSs have been widely used in biomedical
applications, environmental monitoring, food safety, and clinical diagnosis for detecting various
biomolecules and chemical contaminants, including infectious agents, nucleic acids, proteins,
cells (i.e. cancer cells), veterinary drugs, and toxins. The most well-known applications of PLFSs
are glucose test strips and pregnancy test strips.
A general PLFS consists of a series of chromatographic pads containing dry reagents which
can be activated by the fluid samples. Each chromatographic pad possesses different capillary
properties and capacity in order to transport fluid smoothly and efficiently. A PLFS contains four
chromatographic pads, including the sample pad, conjugate pad, nitrocellulose membrane and
absorption pad. Details about each component functions as well as the assembly of the PLFS are
listed below and illustrated in Figure 1.1.
Sample pad: It is used to promote and distribute the sample fluid to the conjugate pad evenly.
In this dissertation, cellulose fiber (17 mm × 30 cm, Millipore) was employed as the sample pad.
Conjugate pad: It is made from glass fiber. The glass fiber can easily adsorb aptamer, DNA or
antibody labeled nanoparticles (signal reporters). In this dissertation, glass fiber of 8 mm × 30
cm was utilized.
Nitrocellulose (NC) membrane: The most important component of the PLFS is the NC
membrane. The pore size and the material properties of the membrane influence the flow rate
(reaction time), the binding stability and the width of the test zone as well as the sensitivity of the
entire system. In this dissertation, the NC membranes with the dimensions of 25 mm × 30 cm
and pore size of 0.22 μm and 0.45 μm were employed.
Absorption pad: The function of the absorption pad is to adsorb the excess fluid from the
device while acting as a sink. Capillary effects draw fluid through the NC membrane from the
sample pad into the absorption pad, maintaining constant motion until an equilibrium in capillary
pressure is achieved. Therefore, the absorption pad enables more target analyte contained sample
fluid to be extracted and detected over an increased time interval, leading to an improved
sensitivity. In this dissertation, cellulose fiber with the dimensions of 17 mm × 30 cm was used
as absorption pad.
4

Assembly of the PLFS: The sample pad, conjugate pad, NC membrane and absorption pad
were laminated to a plastic adhesive backing layer (60 mm × 30 cm, Millipore). Each component
was overlapped by 2 mm to ensure the migration of liquid throughout the PLFS. The mounted
paperboard was cut lengthways and divided into individual PLFS with a 3-mm width by a
guillotine cutter and then stored in a dry state. In a typical assay, a certain amount of sample
solution is loaded onto the sample pad of a PLFS. Subsequently, the sample solution migrates by
capillary action and successively passes the conjugate pad, NC membrane and finally arrived at
the absorption pad.

Figure 1.1. Schematic illustration of a blank PLFS.
The mechanism of a PLFS is based on the combination of signal reporting and interfacing
biological recognition events between biorecognition molecules, such as the interaction between
an antibody with an antigen. On conjugate pad, detection reagents are immobilized, which
contains detection biomolecules labeled signal reporters. On test zone and control zone, capture
reagents and control reagents are respectively functionalized. There are two most frequently
employed interaction formats for capturing target analyte on the detection zone of a PLFS:
competitive format assay and sandwich format assay. Their corresponding response is inversely
proportional to and proportional to the concentration of the analyte respectively. The competitive
format works best for the target molecules with low molecular weight or presenting single
specific antigen. The competitive format contains two sensing mechanism: 1) antibody coated
format (Figure 1.2b): the competition between target antigen and signal reporter linked antigen.
In this format, the specific antibody is firstly immobilized on the test zone. During the detection,
the target antigen and signal reporter labeled antigen would compete for binding on the specific
antibody on the test zone; 2) antigen coated format: the competition between antibody/signal
5

reporter and the complex of antigen-antibody/signal reporter (Figure 1.2c). The target analyte
contained sample solution is firstly incubated with the specific antibody/signal reporter to form
the antigen-antibody/signal reporter. The resulting complex would compete with antibody/signal
reporter for binding on the specific antigen immobilized test zone. Besides the above mentioned
competitive format, another format is sandwich structure based format. In this format of assay,
detection antibody is firstly functionalized with signal reporters; while the capture antibody is
immobilized on the test zone. As shown in Figure 1.2a, during the detection, a sandwich
structure of antibody-antigen-detection antibody/signal reporter is formed on the test zone of the
PLFS. On the control zone of the PLFS, it is immobilized with secondary antibodies, which is
employed for capturing the excess detection reagents from the test zone. The control line is
utilized to indicate that the test strip functions properly.

Figure 1.2. Schematic illustration of the operation principle of sandwich format assay (a) and
competitive format assay with antibody coating type (b) and with antigen coating type (c).
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1.6 STRATEGIES FOR IMPROVING TEST STRIP PERFORMANCES
Nanomaterials

possess

unique properties,

such as large surface area,

excellent

biocompatibility, outstanding conductivity and catalytic ability. Employment of nanomaterials
exhibits great promise in elevating sensor performances. For example, the electron transfer rate
can be elevated from 700 to 5,000 when gold nanoparticles (GNPs) were immobilized into a
biosensor.5 In addition, in an enzyme labeled biosensor, nanomaterial modifications can offer
diverse microenvironment and more freedom of orientation for enzymes.6 Moreover, the stability
of enzymes can be improved when enzymes were linked with GNPs.7 The properties of
nanoparticles strongly depend on their size and morphology.8 For example, in aqueous solution,
spherical GNPs with an average diameter of 20 nm exhibit strong absorption at ~ 520 nm in
wavelength, which makes the GNPs present red color. While the GNPs start to aggregate, the
absorption peak shifts to longer wavelength and the color of the GNPs changes to blue
correspondingly. This unique property brings about many developments of binding-induced
aggregation sensors.9 In a PLFS, GNPs are the most extensively employed signal reporters
owing to their inherent advantages, including intense optical properties, vivid color and
biocompatibility. In addition, the optical properties, size and morphologies of GNPs can be
simply adjusted by changing the ratio between the reductant (sodium citrate) with HAuCl4,
offering PLFS with diverse designs and developments for different sensing demands.10 The
detection sensitivity of GNPs tagged PLFSs can be further elevated through nanoparticlepromoted precipitation of gold or silver around GNP tags. Such precipitation enlarged the size of
the NP-tags and enhanced the optical intensity of the test line, which amplifies the events of
biorecognition, meanwhile benefits the colorimetric signal readout, leading to an elevation in
detection sensitivity.11 Another effective approach for improving the GNP-PLFS sensitivity is to
co-label enzyme onto GNP surfaces and then introducing enzyme substrates for amplifying
signals. The most commonly used enzyme and enzyme substrate in PLFS is horseradish
peroxidase (HRP) and TMB/H2O2. In a typical assay, after the HRP labeled GNPs are captured
on the test area, the substrate TMB/H2O2 is introduced to improve the test line intensity.
Compared with the conventional PLFS, the enzyme functionalized PLFS can realize one to two
orders of magnitude improvement in detection sensitivity.12 Besides HRP, glucose oxidase and
alkaline phosphatase are also the good choices for enzyme catalytic amplification. Polymerase
chain reaction (PCR) is an effective approach for amplifying DNA concentrations with thousands
7

to millions of more copies of that particular DNA segment. Modifying and integrating the
polymerase reactions into PLFSs can significantly improve the detection sensitivity. A new
strategy called strategy isothermal strand-displacement polymerase reactions (ISDPR) was
developed and integrated into PLFSs to overcome the disadvantages of PCR. Compared with
conventional PCR, no thermal cycling is required in the ISDPR-PLFS. In addition, the
amplification procedure was significantly shortened to less than half an hour.13
Besides GNPs, magnetic nanoparticles, microparticles, fluorescent dyes and quantum dots
have also been employed into PLFSs as signal tags. The use of magnetic beads can offer the
PLFSs with improved sensitivity. Since the noise from nonspecific adsorption was reduced by
the magnetic separation procedure, while the signal was elevated owing to the large surface area
of magnetic beads. Fluorescence techniques have been extensively applied in biological sensing
on PLFS. Their performances are largely dependent on the physicochemical properties of the
employed fluorophores. Several experimental parameters should be taken into account when
choosing a fluorophore, including excitation and emission spectra, fluorescence intensity,
lifetime and emission anisotropy. Organic dyes are often used as the fluorophores in biological
research owing to their small sizes, which are suitable for conjugation with biomolecules.
Additionally, various dyes with characteristic excitation and emission spectra are commercially
available and the corresponding protocol for functionalization is well established. However, the
photobleaching, narrow excitation spectra and low luminescent restrict their further applications.
The employment of quantum dots (QDs) into fluorescent biosensors can address these
challenges and meet the demands of fluorescent research owing to their unique properties,
including resistant to photobleaching (fluorescence lifetimes: 1-10 ns vs 10-100 ns), sizedependent emission, narrow emission bandwidths and high levels of brightness.14 For example,
the values of molar absorption coefficients at the first absorption band of QDs are generally
larger than the organic dyes (100,000–1,000,000 M–1 cm–1 vs 25,000–250,000 M–1cm–1); while
the quantum yields are 0.1–0.8 (visible), 0.2–0.7 (near-infrared (NIR)) from QDs and 0.5–1.0
(visible), 0.05–0.25 (NIR) from organic dyes. Additionally, with the light illumination, QDs can
emit light of specific frequencies. The emission frequencies can be precisely tuned by changing
the sizes and components of QDs, which offers QDs the flexibility for multiple detections with
different emission peak positions.15 Lin’s group reported a QDs based fluorescent PLFS for rapid
(10 min) detection of protein in both aqueous solutions and spiked human plasma samples.16 The
8

quantification for target protein was based on recording the fluorescent intensity of QDs that
were captured on the test zone of PLFS through the specific biorecognition between antigen and
antibody. LODs for target protein of 1 and 8 ng/mL were obtained from aqueous solutions and
spiked human plasma samples respectively. This QDs based fluorescent test strip can be
extended for the fast and simple analysis of other protein biomarkers.
Recently, NIR nanomaterials attract increasing attention in bioassays due to that the biological
tissues are highly transparent to the NIR light (700 to 1,100 nm). Studies showed that various
nanomaterials present optical absorbance in this special NIR spectral window, such as NIR-QDs,
SWNTs,17 graphene dots,18 and upconversion-luminescent phosphors (UCPs).19 Among the NIR
NPs, QDs exhibit flexibility for multiple detections; while carbon nanomaterials and UCPs show
low toxicity to biological samples, which are well suited for biomolecule analysis. As a result,
the employment of NIR into PLFS shows an increase in sensitivity and anti-interference capacity
in biological fluids compared with that of the conventional GNP-PLFSs.
Signal quantity system is also crucial for improving PLFS performances, owing to the fact
that proper signal recording approach can avoid signal loss, meanwhile generate stable signal
responses, leading to the elevation of sensitivity and stability of a biosensor. In general, signal
recording system is selected according to the employed signal reporters. For example, a
colorimetric strip reader is designed for recording the color intensity from the test line of a GNP
labeled PLFS; while a fluorescent strip reader is designed for recording the fluorescent signal
from the test line of a QDs, fluorescent dye or UCPs functionalized PLFS. Recently, a concept of
thermal contrast was proposed into the PLFS as the signal quantity system for improving the
signal intensity and detection sensitivity.20 A laser/light emitting diode (LED) and an infrared
temperature gun were employed instead of the conventional strip reader as the signal quantity
system. The light was used to irradiating the GNPs captured on the test line while the infrared
temperature gun was employed to record the thermal contract from the heated GNPs. As a result,
this thermal contract mechanism endowed the GNP-PLFS with an improvement of 32-fold in
detection sensitivity. The performance can be further improved through the employments of
higher-absorbing NPs and low-absorbing PLFS backing materials.21
The capacity of simultaneous detection of multiple biomarkers is another important factor to
elevate the sensor performances, since measurement of multiple biomarkers is considered as the
most promising approach to reliable diagnosis or prediction of diseases. For example, the
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detection sensitivity for ovarian cancer was improved from 65% to 74% and the detection
specificity was elevated significantly from 52% to 94% when multiple protein biomarkers were
analyzed.22 Moreover, compared with single detection, simultaneous detection offers additional
advantages, including timesaving, reduced operations, cost and samples.23 Simultaneous
detection in PLFS can be realized through dispensing capture reagents on different test line
respectively; meanwhile functionalizing signal tags with different detection reagents towards
specific target biomolecules. In general, four test-lines is the maximum allowable dispensed
amount on a PLFS according to the chemical reagent consumptions of a PLFS with general
dimensions (3 mm × 60 mm). The signal tags functionalized detection reagents can be either
mixed and then loaded on one conjugate pad of a PLFS, or loaded onto different conjugate pads
of the multiple conjugate pads modified PLFS.
In summary, the major advantages of PLFSs are portable, fast, low-cost and easy-operated.
However, most of the current state-of-the-art PLFSs can only function in buffers or artificial
solutions. It is still a formidable challenge to apply them in real applications owing to the relative
low sensitivity, which cannot meet the demands for detecting early stage of disease biomarkers.
Additionally, the high interference of nonspecific biomolecules in complex human fluids
dramatically affects the sensing specificity and stability. By taking the advantages of explosive
development of nanotechnology, many advanced techniques and strategies can be employed to
solve the problems.
1.7 TECHNIQUE OF SURFACE-ENHANCED RAMAN SCATTERING
Raman spectroscopy has been intensively explored in the applications of biological sensing
and medical diagnostics. However, the Raman scattering is much weaker than the other optical
techniques, which is considered to be the main hurdle for ultrasensitive measurement for relative
low sample concentrations.
Metallic nanomaterials possess unique optical properties that are related to the collective
oscillation of free conduction electrons in nanostructures in resonance with the incident
electromagnetic radiation. These nanostructured materials are capable of providing surface
plasmon resonances (SPRs) and can be utilized in biosensing technologies based on the principle
that the intensity and the position of SPR is sensitive to the changes in the dielectric properties
(refractive index) in the vicinity of the plasmonic surfaces. SPR occurs in two different forms:
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propagating surface plasmon polaritons (SPPs) and localized SPR (LSPR). SPPs are the charge
oscillations associated with an electric field propagating along a metal-dielectric interface. These
oscillations are decaying exponentially in the perpendicular direction. LSPR occurs when the
dimensions of a metallic nanostructure are much smaller than the incident wavelength, leading to
non-propagating local oscillations of the plasmons around the nanoparticles. By utilizing
plasmonic materials, numerous nanostructures have been developed as signal amplifiers for
sensitive optical sensing. Surface-enhanced Raman scattering (SERS) is a powerful technique
that possesses ultra-sensitivity by amplifying the Raman scattering signal by orders of magnitude
if a molecule is associated to the surface of plasmonic nanomaterials.24 The most widely
employed SERS-active metals are Au, Ag and Cu. The Raman signal enhancement of SERS is
attributed to two mechanisms: chemical enhancement and electromagnetic (EM) enhancement.
The chemical enhancement (10-100 enhancement factor) contributes to the electron interaction
between the metallic substrate and the molecule absorbed on its surface; while the
electromagnetic enhancement (104 and 1012 enhancement factor) induces the dominant
contribution and it arises from the light-induced collective oscillation of conduction electrons
from the metallic substrate.25 During developing of a biosensor, the SERS-active nanomaterials
can be integrated as labels or patterned substrates.
“Hot spots” are generated inside the gaps or around the sharp edges, corners or tips of the
SERS-active nanomaterials, where the EM field is particularly intense, leading to extraordinary
enhancement of SERS signal. Nowadays, a SERS enhancement factor of 1014 have been
achieved through precisely fabricating the nanostructure, which is capable of sensing single
molecule.26 SERS is also well-suited for multiple detections because of the “fingerprint” feature
to produce distinct spectra from components in multiplexing. On the other side, this “fingerprint”
ability can also increase the anti-interference resistance to nonspecific molecule in complex
sample matrices. Therefore, SERS technique is well-suited to be used for ultrasensitive
measurement in biological matrices.
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Figure 1.3. Structure of sandwich typed SERS probe with SiO2 coating.
Conventional SERS biosensors are developed using bare GNPs, which supports localized
surface plasmon resonance (LSPR) for the absorbed Raman molecule to generating SERS signals.
However, bare GNPs-based SERS probes are unstable in aqueous solutions with high ionic
strength or in blood samples, which raises serious concern about reliability and robustness. In
addition, the SERS labels are easy to desorb from the nanoparticle surface, leading to reductions
of stability and signal intensity during the detection. A solution to this issue is to coat the SERS
labels adsorbed nanomaterials with a thin protecting layer, such as polyethylene glycol (PEG) or
SiO2 to form a sandwich-typed SERS label. The protective layer has several advantages: (i) it
encapsulates numerous Raman reporters into a single particle, which enhances the SERS
response; (ii) the protecting layer avoids the leaking out of Raman reporters, which increases the
signal stability; (iii) it offers the capability for further surface-functionalize with biomolecules;
(vi) it makes the nanoparticles water-soluble and biocompatible. In this dissertation, Au nanostar
will be employed as the SERS substrate for the absorbed Raman molecule to generating a strong
plasmonic field foe amplifying SERS signal. While the Raman reporter molecules are
sandwiched between an Au nanostar and a thin silica shell. This structure prevents Raman
reporter molecules from leaking out. The Au nanostar generates a strong plasmonic field for
amplifying SERS signal. The silica shell not only provides a platform for bioconjugation but also
makes the SERS probe water-soluble. The structure of the sandwich typed SERS probe is
illustrated in Figure 1.3.
1.8 TECHNIQUE OF NEAR-INFRARED FLUORESCENCE (NIRF)
Fluorescence techniques have been extensively applied in biological sensing, cell imaging and
screening. Their performances are largely dependent on the physicochemical properties of the
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employed fluorophores. Several experimental parameters should be taken into account when
choosing a fluorophore, including excitation and emission spectra, fluorescence intensity,
lifetime and emission anisotropy.27 Organic dyes are often used as the fluorophores in biological
research owing to their small sizes, which are suitable for conjugation with biomolecules.
Additionally, various dyes with characteristic excitation and emission spectra are commercially
available and the corresponding protocol for functionalization is well established. However, the
photobleaching, narrow excitation spectra and low luminescent restrict their further
applications.28
The employment of near-infrared fluorescence (NIRF) attracts increasing attention in
biological applications owing to that it can reduce the damage of biological samples and avoid
the photobleaching and background interference when visible fluorophores (VisF) are utilized.29
This is because that due to reduced absorbance and minimal scattering, the NIR radiation
possesses high penetration ability towards tissues and biological matrices. Meanwhile, the NIR
wavelengths falls within the biological windows with low background fluorescence signals,
which provides elevated signal-to-noise ratio.30 In this dissertation, NIRF dye-encapsulated silica
nanoparticles have been developed. The superior properties of such nanoparticles include
amplified signal, outstanding photostability, water-solubility and viability of surface
modification. For example, the silica layer enables a large number of NIRF dye molecules to be
encapsulated inside of one single silica nanoparticle, which can dramatically magnify its
luminescence signal. In addition, the external silica layer protects the dyes from the surrounding
matrix or other environment, which minimizes the photobleaching phenomena and increases its
photostability. Moreover, silica possesses flexible routes for surface modifications with various
types of functional groups (e.g. –NH2, -COOH, -SH), which allows its conjugation with different
biomolecules during bioassays.31
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Chapter 2: SURFACE ENHANCED RAMAN SCATTERING TEST STRIP
FOR PLASMA TESTING
2.1 TRMATIC BRAIN INJURY
Traumatic brain injury (TBI) is a leading cause of death and disability in both the United
States and the developed world. Approximately 2.8 million TBI-related emergency department
(ED) visits, hospitalizations and deaths occurred in the United States in 2013. The estimated
direct and indirect medical costs of TBI were estimated to be in excess of $76 billion in 2010.
The current ED standard of care for the initial assessment of a patient’s potential TBI includes
employment of the Glasgow Coma Scale (GCS), in which a clinician numerically assesses the
brain impairment based on the bedside physical examination, and computed tomography (CT)
scans. These screening tools are presently used for initial clinical management and prognosis of
TBI.32 However, they cannot provide information on pathophysiological processes, and they are
not very sensitive or specific, particularly in the case of mild or moderate TBI. On the other hand,
some ED patients with traumatic injuries and a poor GCS are subject to brain impairment due to
intoxication from alcohol and/or drugs instead of from a true brain injury. Although early CT
scans are useful for detection of intracerebral hemorrhage, they are often less effective at early
detection of the more common cerebral contusions and diffuse axonal injury. Additionally, there
has been a growing concern regarding radiation exposure from the use of screening CT scans in
patients with possible TBI. Magnetic resonance imaging (MRI) is much more sensitive for
detecting early TBI and does not expose patients to radiation. However, these studies are
expensive and time-consuming, often require patient sedation, and are frequently unavailable at
the ED.33 Early and accurate diagnosis of TBI is clinically important, as currently routine yet
potentially unnecessary screening imaging might be avoided. Additionally, many patients with
even mild TBI may experience short- or longterm sequelae including changes in attention and
memory and emotional disturbances that may benefit from early diagnosis and intervention.
Importantly, TBI clinical trials such as those testing potential early therapies aimed at, for
example, decreasing secondary injury have been severely hampered by the dilemma of early
diagnosis of true TBI as opposed to intoxication, with this “noise” requiring an increase in
sample size and expense, and possible dilution of the measurable effect of the potential therapy.
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Measurement of protein biomarkers can provide an alternative route for rapid and accurate
disease diagnosis. Protein biomarkers are present in human fluids, such as blood, saliva, or urine,
which makes the tests much less invasive, rapid, and inexpensive and avoids the radiation
involved with CT scans and time, sedation, and expense of MRIs.
The most common TBI biomarkers are glial fibrillary acidic protein (GFAP), S100-β, and
neuron-specific enolase (NSE), which are released into circulation after the brain damage
occurs.34 Several methods have been employed to measure the protein biomarkers, including
enzyme-linked immunosorbent assay (ELISA), Western blot, and agarose. However, those
methods generally involve time-consuming operation processes and large sample volume and
require expensive instruments, which cannot be used as the point-of-care (POC) analytical tools
for rapid and low-cost clinical diagnosis. Therefore, great efforts have been devoted to
developing portable biosensors toward POC testing. Recently, several biosensors have been
employed for NSE biomarker detection, including electrochemistry,35 chemiluminescence,36 and
field-effect transistor.37 However, most of these biosensors were tested in buffer solutions and
did not demonstrate the direct detection of NSE biomarker in human fluidic samples. Moreover,
many biosensors still need multiple steps of operation in vials, which are not user-friendly.
Hence, it remains a challenge for those sensors to be used in a POC setting.
PLFSs have received increasing attention as POC tools because they are inexpensive, userfriendly, and easy to operate.38 Colorimetric,12 fluorescent,16 and electrochemical39 transducers,
are commonly used in PLFS. Unfortunately, they usually suffer from poor sensitivity and serious
interference from sample matrices when they are used in blood plasma samples. In contrast,
surface enhanced Raman scattering (SERS) has strong anti-interference ability in real-world
samples because the wavelengths of both the excitation light and the scattering Raman signals
can be tailored into the near-infrared biological transparency window, and Raman spectra are
characteristic of fingerprint signatures of target molecules.40 Several papers have recently
reported the incorporation of SERS transducers into PLFS for detection of proteins and nucleic
acids in water or buffer solutions. In these reported SERS-PLFS, bare Au nanoparticles were
used as the SERS substrates.41 Bare Au nanoparticle-based SERS probes are unstable in aqueous
solutions with high ionic strength or in blood samples, which raises serious concern about
reliability and robustness.42 Hence, the SERS-PLFS based on bare Au nanoparticle have not been
applied to blood samples yet. To address the instability issue of bare gold nanospherebased
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SERS probes, Au nanostar@Raman Reporter@silica sandwich nanoparticles have been
developed as the SERS probes in our research group, in which the Raman reporter molecules are
sandwiched between an Au nanostar and a thin silica shell. This structure prevents Raman
reporter molecules from leaking out. The Au nanostar generates a strong plasmonic field for
amplifying SERS signal. The silica shell not only provides a platform for bioconjugation but also
makes the SERS probe water-soluble. Our previous study has shown that these types of
sandwich SERS probes are very stable in aqueous solutions with high ionic strength while bare
Au nanoparticles tend to aggregate under the same condition. In the present work, the sandwich
SERS probes are incorporated into a PLFS to detect the NSE biomarker in blood plasma. By
comparison, a colorimetric PLFS with bare plasmonic Au nanospheres is also used for protein
detection. Compared to the colorimetric PLFS, the SERS-based PLFS shows much higher
sensitivity in blood plasma samples. To the best of our knowledge, this report for the first time
demonstrates the successful detection of protein biomarkers in clinical blood plasma samples
using a SERS-based PLFS without any purification or separation procedure. The results show a
great potential of SERS-PLFS in the POC setting.
2.2 MATERIAL AND METHODS
2.2.1 Reagents and Materials
Malachite green isothiocyanate (MGITC) was purchased from Molecular Probes, Inc. 4Mercaptobenzoic acid (technical grade, 90%) (4-MBA) was purchased from Sigma-Aldrich. 3Triethoxylsilylpropyl

succinic

anhydride

(TEPSA)

was

obtained

from

Gelest

Inc.

Nhydroxysuccinimide (NHS), 1-ethyl-3-(3-(dimethylamino)- propyl) carbodiimide (EDC), and
tetraethyl orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, sucrose,
Na3PO4·12H2O, Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), BSA (bovine serum
albumin) and sodium chloride were acquired from Sigma-Aldrich and used without further
purification. Sucrose was purchased from VWR. Goat antihuman IgG polyclonal antibody, mice
antigoat IgG polyclonal antibody, IgG from human serum, Neuron-specific enolase from human
brain (NSE), and antineuron-specific enolase antibody were procured from Sigma-Aldrich.
Neuronspecific Enolase Quantikine ELISA Kits were purchased from R&D System and Eagle
Bio. The blood plasma was purchased from US Biological Life Science (P4252-56 Plasma,
Human, IgG Free). Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700),
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laminated cards with Hi Flow plus cards (HF090MC100 with RK12312 Membrane (0.45 μm)),
and nitrocellulose membrane (RK13464 (0.22 μm)) were purchased from Millipore (Billerica,
MA). Clinical blood plasma samples were collected from TBI patients presenting to the ED as
part of the Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen pilot clinical
trial for traumatic brain injury (RESCUE-TBI) conducted by researchers at the University of
Texas Southwestern Medical Center and Parkland Hospital. As part of this study, the clinical
samples were serially collected at various time points over the first 5 days following TBI and
stored at −80 °C prior to measurement. All work conducted in the pilot clinical trial was
approved by the National Heart, Lung, and Blood Institute’s Resuscitation Outcomes
Consortium Protocol Review Committee and Data Safety Monitoring Board, the U.S. Food and
Drug Administration, and the University of Texas Southwestern Medical Center Institutional
Review Board. Use of these deidentified human samples at West Virginia University was
approved by the West Virginia University Institutional Review Board.
2.2.2 Instruments and Characterization
All Raman spectra were acquired with a portable B&W Tek i-Raman Plus. Fourier transform
infrared (FT-IR) spectra were obtained under the attenuated total reflection (ATR) mode with
Thermo Nicolet 6700 spectrometer. The nanoparticles were characterized with a transmission
electron microscope (TEM, JEOL JEM-2100F) at an acceleration voltage of 200 kV. UV−visible
absorption spectra were obtained with a Shimadzu UV-2550 spectrometer.
2.2.3 Synthesis of Nanoparticles and Conjugation with Detection Antibodies
The Au nanostars, the SERS probes, and the nanoparticles conjugated with detection
antibodies were synthesized according to our previous paper.40 The preparation procedure is
illustrated in Figure 2.1. Briefly, the Au nanostar@Raman molecule@Silica sandwich SERS
probes were synthesized by adding 1.0 μM Raman molecules into the Au nanostar suspension.
Then, 200 μL of 1% TEOS and 15 μL of ammonium solution were added into the mixture,
successively. After the SERS probes were formed, the resulting solutions were centrifuged and
resolved in 500 μL of ethanoic solution. The Au nanostars were coated with a 2−3 nm thick
silica layer on the outer surface. Figure 2.2 shows the TEM images of the sandwichtyped SERS
nanoparticles.
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Figure 2.1. Schematic illustration of the preparation process of the SERS probe conjugated with
the detection antibody.

Figure 2.2. TEM images of the Au nanostar@MBA@SiO2 sandwich nanoparticles a) low
magnification and b) high magnification.
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Figure 2.3. UV-visible absorption spectra of the Au nanostar and the Au nanostar@Raman
molecule@silica sandwich nanoparticles.

Figure 2.4. FT-IR spectra of the carboxyl-group functionalized SERS probe. The peak at 1704
cm-1 peak is assigned to the C=O stretching vibration in COOH of TEPSA.
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Figure 2.5. FT-IR spectra of the detection antibody functionalized SERS probe. The peaks at
1649 and 1551 cm-1: correspond to the N-H bending in the antibody.
The coating of the silica layer was further approved by the UV−visible absorption spectra.
That is, the localized surface plasmon resonance (LSPR) absorption band of the nanoparticles
shifted from 770 to 790 nm after it was coated with silica (Figure 2.3). Next, 100 μL of TEPSA
was added to the SERS probe solution and then incubated overnight to achieve the carboxylgroupterminated SERS probes. In the current study, the conjugation of carboxyl-group onto the
surface of SERS nanoparticles was confirmed by FT-IR spectra (Figure 2.4). The carboxylgroupterminated sandwich nanoparticles were then activated by adding a PBS buffer solution
containing 50 mM NHS and 200 mM EDC and then incubated for 1 h. Subsequently, 100 μL of
1.0 mg/mL detection antibody was added, and the mixture was incubated overnight. After that,
the mixture was centrifuged and washed with a PBS buffer three times to remove excessive free
antibody. The resulting SERS probe conjugates were stored in 100 μL of eluent buffer (20 nM of
Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% sucrose) solution for future use.
The successful conjugation of detection antibody onto SERS nanoparticles was confirmed by the
FT-IR spectra (Figure 2.5).
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Figure 2.6. Schematic illustration of the operation principle of SERS paper-based lateral flow
strip (PLFS). (a) Top and side views; (b) side view before and after detection of protein
biomarker; (c) optical photos of PLFS assembled in cassettes in the presence (upper) and absence
(bottom) of the target protein.
2.2.4 Preparation of Test Strip
Figure 2.6 shows the schematic diagram of the PLFS, which consists of four components: a
sample pad, a conjugate pad, a nitrocellulose membrane (NC membrane), and an absorbent (or
wick) pad. All the components were mounted on a common backing layer (typically an inert
plastic, e.g., polyester). The sample pad was saturated with a Tris-HCl buffer (pH 8.0) containing
0.23% Triton X-100 and 0.05 and 0.15 M NaCl. The pad was then dried at 37 °C for 2 h and
stored in a desiccator at room temperature (RT). Then, 200 μL of 2.5 mg/mL capture antibodies
and secondary antibodies were dispensed onto the NC membrane by a homemade dispenser to
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form a test line and a control line, respectively. The capture antibody and the secondary antibody
were dispensed twice and once, respectively. The distance between the test line and control line
was 3 mm. The membrane was then dried at 37 °C for 1 h and stored at 4 °C under a dry
condition. Successful conjugation of antibody onto the NC membrane was confirmed by FT-IR
spectra (Figure 2.7), in which the peak at 1534 cm−1 indicated the N−H bending. The SERS
probes conjugated with the detection antibodies were dropped onto the conjugate pad. Finally, all
the four processed components were assembled onto a plastic adhesive backing layer. The
components were overlapped with 2 mm to ensure that the solution was able to flow through the
whole strip. Each strip was cut to be 3 mm wide by a paper cutter (Swingline 12 in. ClassicCut
Lite Trimmer). Before testing, 7 μL of SERS probes conjugated with the detection antibody was
loaded onto the conjugate pad of PLFS. During testing, 100 μL of sample solution containing a
certain concentration of analytes was dropped on the sample pad of PLFS.

Figure 2.7. FT-IR spectra of the capture antibody functionalized NC membrane. The peak at
1534 cm-1 is assigned to the N-H bending.
2.3 RESULTS AND DISSCUSSION
2.3.1 Operation Principle
The prepared PLFS is a carrier device containing dry reagents that are activated by applying a
fluid sample (Figure 2.6b). Once the sample solution containing analyte is dropped onto the
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sample pad of PLFS, the solution will flow to the conjugate pad by the capillary force. On the
conjugate pad, the target protein molecules interact with the SERS probes conjugated with
detection antibodies to form a complex of target protein-detection antibodies labeled SERS
probes. The resulting complex continues to move until it is captured by the capture antibody on
the test line. At this moment, the SERS probes are accumulated on the test line through the
formation of a sandwich-type configuration of SERS probe (linked with detection antibody)protein-capture antibody. The excessive SERS probes linked with detection antibodies continue
to migrate and then are captured by the control line where the secondary antibody is immobilized.
As a result, two greyish bands are displayed on the test line and the control line, respectively
(Figure 1c). A portable Raman spectrometer is employed to record the SERS signal. Under
excitation by a 785 nm laser, the SERS signal is generated from the MBA (Raman reporter)
molecules inside of the SERS probes. As shown in Figure 2.8, the SERS spectra acquired from
the test line are characteristic of both the Raman reporter and the NC membrane. The amount of
SERS probes captured on the test line is in proportion to the concentration of a target protein,
which is employed for quantification. In the absence of the target protein, only the control line
shows greyish color, indicating that the test strip functions properly.
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Figure 2.8. SERS spectra of the Au sphere@MBA@silica sandwich SERS probes on the NC
membrane and Au film.
2.3.2 Optimization
In order to optimize the performance of the PLFS, it was used to detect 1 ng/mL of human
IgG. The human IgG was selected as the model analyte because this protein is well-known, and
its testing is much more inexpensive compared with NSE testing. In the optimization study,
MIGTC was used as the Raman reporter initially, and the SERS spectra with a characteristic
peak at 1173 cm−1 were recorded. The flow rate of the sample solution significantly influences
the efficiency of binding between antibodies and antigens, as well as the signal intensity and the
signal-to-noise (S/N) ratio. Generally, the flow rate of a liquid in the PLFS is dependent on the
surfactant content and the pore size of the NC membrane. The surfactant in the running buffer is
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an important component, which regulates the binding time between an antibody and its antigen
and, meanwhile, mitigates the nonspecific adsorption of SERS probe on the test line. TWEEN 20
was chosen as the surfactant, and its content in the running buffer was optimized. Figure 2.9a
reveals that the S/N ratio of the SERS peak increased with the growing content of TWEEN 20
content in the running buffer until it reached 0.07%. Further increase in the TWEEN 20 content
led to a decrease in the S/N ratio, as a high TWEEN 20 content caused a high flow rate of
running buffer, leading to a significant decrease in the binding time between the antibody and the
antigen. Another parameter governing the flow rate is the pore size of the NC membrane.
Reducing the pore size decreases the flow rate and increases the time of binding between the
target analyte and the antibody. As shown in Figure 2.9b, the S/N ratio for small pores (0.22 μm
in a diameter) was higher than that for large pores (0.45 μm). In addition, the signal intensity and
the detection sensitivity are significantly affected by the detection antibody-linked SERS probe
amount on the conjugation pad and the capture antibody immobilized on the test line because
both of the factors affect the ability of PLFS to capture the antigen. As shown in Figure 2.9c, d,
the optimal detection antibody-linked SERS probe amount was 7 μL, and two-time dispenses
were the best.

Figure 2.9 Optimization of the experiment conditions for SERS-PLFS. a) Effect of the surfactant
TWEEN 20 content in the running buffer on the S/N ratio of PLFSs, b) effect of the membrane
type (pore size) on the S/N ratio, c) effect of the volume of SERS-detection antibody conjugate
on the S/N ratio, and d) effect of the dispensing time of the capture antibody on test line on the
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S/N ratio.
2.3.3 Performance of Test Strip
A comparative study was performed on the use of two types of Raman reporters (MGITC and
MBA). The SERS-PLFS with two different Raman reporters were used to measure various
concentrations of human IgG in the PBS buffer. Figure 2.10 shows the MBA-SERS spectra and
the corresponding calibration curve (Figure 2.10b). The overall SERS intensity obtained from
the MBA-based PLFS (Figure 2.10a) was stronger, and the peaks were much sharper than those
from the MGITCbased PLFS (Figure 2.10c). The calibration curve in Figure 2.10b was
obtained by plotting the SERS peak intensity at 1076 cm−1 from MBA as a function of the
logarithmic concentration of human IgG. The calibration curve in Figure 2.10d was obtained
from the PLFS by recording the SERS peak intensity at 1173 cm−1 from MGITC. The slope of
calibration curve for the MBA-PLFS was 15 times higher than that for the MGITCPLFS. The
limit of detection (LOD) was determined at the signal-to-noise ratio of 3, which was 0.02 and
0.05 ng/mL for the MBA-PLFS and the MGITC-PLFS, respectively. In short, the MBA-PLFS
exhibited higher sensitivity and lower LOD than the MGITC-PLFS. Therefore, MBA was
employed for analyte detection instead of MGITC in the following experiments. The
reproducibility of the MBA-based PLFS was examined. Human IgG samples at three levels were
tested, and five SERS spectra were acquired at each level of human IgG. The SERS peak
intensity of MBA at 1076 cm−1 exhibited good signal reproducibility. The corresponding relative
standard deviation (RSD) values of MBA peak intensities were 7.0%, 4.1%, and 5.9% for
measuring 10, 1, and 0 ng/mL of IgG in PBS, respectively.
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Figure 2.10. SERS spectra obtained from the SERS-PLFS with different Raman report
molecules. (a) MBA as Raman reporter and the corresponding calibration curve (b); (c) MGITC
as Raman reporter and the corresponding calibration curve (d).
2.3.4 Measurement of Anti-Interference Ability in Blood Plasma.
In order to study the anti-interference ability in real-world biological fluids, the developed
SERS-PLFS was employed to measure the human IgG spiked in a PBS solution and in a mixture
of 90% PBS and 10% blood plasma (a specially treated IgG-free blood plasma purchased from
US Biological Life Science (P4252-56 Plasma, Human, IgG Free)), respectively. When the
SERS-PLFS was used for detection of IgG in 100% PBS solution, the calibration curved showed
a linear detection range from 0.5 ng/mL to 0.1 mg/mL (Figure 2.10b), achieving a LOD of 0.02
ng/mL. When it was used to test a mixture of 90% PBS and 10% blood plasma, the calibration
curve showed a linear detection range from 1.0 ng/mL to 0.05 mg/mL (Figure 2.11), achieving a
LOD of 0.08 ng/mL. In addition, the slope of the calibration curve obtained from the mixture of
90% PBS and 10% blood plasma (Figure 2.11) was much smaller than that from 100% PBS
(Figure 2.10b). The results indicated that an abundance of biomolecules present in blood plasma
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affected the binding of antibody to the target protein.

Figure 2.11. Calibration curve of SERS-PLFS with MBA as Raman reporter for detection of IgG
in a mixture of 90% PBS and 10% blood plasma.
2.3.5 Comparison of Performance
Comparative studies were performed on the colorimetric and SERS PLFS. The plasmonic Au
nanoparticles acted as the sensing transducer in the colorimetric PLFS while the Au
nanostar@MBA@silica sandwich nanoparticles served as the sensing transducer in the SERSPLFS. Figure 2.12a shows that the colorimetric PLFS worked well when it was used to measure
IgG in the PBS solution. The calibration curve showed a linear range from 1 ng/mL to 50 μg/mL
(Figure 2.12c), achieving a LOD of 0.5 ng/ mL. However, when the colorimetric PLFS was
employed for IgG detection in a mixture of 90% PBS and 10% blood plasma, the color intensity
of the test line was much weaker than that tested in a PBS buffer (Figure 2.12b), and a high
LOD (50 ng/ mL) was observed. When the SERS-PLFS was used for detection of IgG in 100%
PBS solution, a LOD of 0.02 ng/mL (Figure 2.10b) was achieved, which was 1 order of
magnitude lower than that of the LOD (0.5 ng/mL, Figure 2.12c) of the colorimetric PLFS. In
contrast, when they were applied to the sample matrix containing blood plasma, the SERS-PLFS
(Figure 2.11) showed much better performance than the colorimetric PLFS (Figure 2.12c). The
SERS-PLFS exhibited a LOD of 0.08 ng/mL, which was 3 orders of magnitude lower than that
(50 ng/mL) of the colorimetric counterpart. This result demonstrated that the SERS-PLFS had
much better antiinterference ability than the colorimetric counterpart when they were applied to
the blood plasma sample matrix.
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Figure 2.12. Optical photos and calibration curves of colorimetric PLFS for detection of IgG
(0−50 μg/mL): (a) in PBS buffer and (b) in a mixture of 90% PBS and 10% blood plasma; (c)
corresponding calibration curves.
2.3.6 Measurement of Protein Biomarker in Diluted Blood Plasma.
The SERS probe is the key to the SERS-PLFS. In our sandwich-structured SERS probe, the
silica shell is vital to ensure the stability of the SERS probe in the real-world blood plasma that
typically exhibits high ionic strength, as shown in our previous paper. Herein, the stability of the
bare Au nanospheres, the silica-coated Au nanospheres, and the silicacoated Au nanostars in the
diluted blood plasma was tested (see Figure 2.13). It was found that the color of the 80% blood
plasma sample containing the bare Au nanosphere became darker after 6 h of incubation, and the
29

bare Au nanospheres were found to be aggregated at the bottom of the vial after overnight. In
contrast, the color of the counterpart samples containing the silica-coated Au nanospheres and
the silicacoated Au nanostar was not altered, and no aggregation was observed after overnight.
This result indicated that the silica shell prevented the nanoparticles from aggregation in the
diluted blood plasma.

Figure 2.13. Stability test results of the bare Au nanospheres, the silica-coated Au nanospheres
and the silica-coated Au nanostars. (a) nanoparticles in water; (b) nanoparticles in a mixture of
80% of blood plasma and 20% buffer solution after sitting for 1 minute; (c) nanoparticles in the
mixture after 6 hours; and (d) nanoparticles in the mixture after overnight.
In the SERS probe, the Au nanostar is chosen as the core rather than the Au nanosphere
because the Au nanostar can result in much higher SERS enhancement than the Au nanosphere.42
This is due to the fact that the Au nanostar possesses a lot of “hot spots” and shows a LSPR band
that is overlapped with the wavelength of excitation laser. Under the optimal experiment
condition, the developed SERS-PLFS was employed to detect various concentrations of NSE
biomarker spiked into a mixture of 20% PBS solution and 80% blood plasma. It is noted that
measurement of NSE in a diluted blood plasma can be finished within 30 min. Prior to NSE
measurement, the baseline concentration of NSE in the blood plasma was measured by a
commercial NSE ELISA kit (R & D System). Three ELISA measurements were performed.
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None of the tests showed any signal response, which indicated that the NSE content in blood
plasma was lower than the LOD (0.038 ng/mL) of the ELISA Kit. Figure 2.14 shows that the
intensity of SERS peak at 1076 cm−1 gradually rises with an increase in the NSE concentration in
a mixture of 20% PBS and 80% blood plasma. The SERS peak intensity (y) versus the NSE
concentration (x) was fitted as y = 6.7x + 275.3 with the relative coefficient (R2) of 0.98,
showing a linear detection range from 1.0 to 75.0 ng/mL, achieving a LOD of 0.86 ng/mL. The
LOD was estimated with three times the standard deviation of negative control divided by the
slope of calibration curve. This LOD was below the cutoff value of NSE concentration (12.4
ng/mL) in blood plasma of TBI patients. The NSE level in TBI patients generally is elevated
to >21.7 ng/mL. Our experimental results show the SERS-PLFS developed in the present work
can work for NSE detection in blood plasma.

Figure 2.14. SERS spectra (a) and calibration curve (b) of SERS-PLFS with MBA as Raman
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reporter for detection of NSE in a mixture of 20% PBS and 80% blood plasma.
2.3.7 Measurement of Protein Biomarker in Clinical Blood Plasma Samples
The calibrated SERS-PLFS was employed to measure the NSE biomarker level in clinical
blood plasma taken from the TBI patients. The same clinical samples were also measured with
the commercial ELISA kits to validate the measurement results obtained from the SERSPLFS.
Figure 2.15 shows the NSE concentrations in six clinical blood plasma samples measured by the
SERS-PLFS and the NSE ELISA kits (R & D System and Eagle Bio), respectively. The results
reveal that the data obtained by the SERS-PLFS were comparable to those by the ELISA. This
result is appealing because the SERS-PLFS has evident advantages over ELISA when applied to
clinical blood plasma samples. The SERS-PLFS is easy to operate, which enables clinical blood
plasma samples to be measured rapidly with a portable Raman spectrometer. The clinical impact
of such an inexpensive and rapid bedside diagnostic tool stands to change practice in the
diagnosis of TBI in both the clinical and research arenas through early, easy, and accurate
detection of true TBI and will reduce the diagnostic radiation exposure, increase the accuracy of
the diagnosis, decrease costs, allow for earlier interventions aimed at mitigating both short- and
long-term sequelae, and improve the quality of TBI clinical trials.

Figure 2.15. NSE concentrations in clinical blood plasma samples, which were measured by
ELISA and the SERS-PLFS, respectively.
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2.4 CONCLUSION
In summary, a SERS-PLFS was successfully developed in the present work. The LOD of
SERS-PLFS was 1 order of magnitude lower than that of the colorimetric PLFS when they were
used for detection of proteins in PBS buffer but was 3 orders of magnitude lower in a mixture of
PBS and blood plasma. This result proves that the SERS-PLFS had much better anti-interference
capability and improved sensitivity in blood plasma-containing sample matrix compared to the
colorimetric PLFS. The key to success of SERS-PLFS is the employment of the Au
nanostar@Raman reporter@silica sandwich nanoparticles as the SERS probes. Such SERS
probes have strong SERS enhancement capability, excellent stability in complex blood plasma
matrix, and good ability of antiinterference. The SERS-PLFS achieved a linear detection range
from 1.0 ng/mL to 75.0 ng/mL toward NSE in a mixture of 80% blood plasma and 20% PBS.
The SERS-PLFS was successfully employed for detection of NSE in clinical blood plasma
samples. Obviously, the SERS-PLFS has advantages over the ELISA approach, including low
cost, portability, short operation time, and simple operation procedure. These merits endow the
SERS-PLFS with great potential to be employed as a POC tool for monitoring the protein
biomarkers in real-world blood samples.
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Chapter 3: PLASMA SEPARATION UNIT IN WHOLE BLOOD TESTING
3.1 BIOMARKER OF CARCINOEMBRYONIC ANTIGEN (CEA)
A critical and challenging future direction in science and engineering is to develop
technologies to improve the health of people in the developing and remote regions of the world.1
However, advanced diagnostic technologies are always centralized and requiring sophisticated
instruments, specialized laboratory personnel and expensive chemicals. Moreover, continuous
and long term monitoring add tremendous time and financial burden on patients due to
soaring costs and frequent travel to hospitals and institutions. These factors have accelerated the
emphasis on the development of low-cost, easy-to-operated and reliable devices to shift
diagnostic testing from medical institutes and laboratories to the sites of patient care.
Paper-based devices appear to be effective tools for providing access to point-of-care (POC)
applications, owing to their advantages of low cost, fast response, portability and ease of use.43
In addition, paper is compatible with biological samples, which allows its application in
analyzing various biomolecules during bioassay.44 Moreover, paper-based POC testing allows
test results to be read out facilely and quickly, which assists in making clinical management
decisions in an immediate and timely manner. The underlying mechanism of a paper-based POC
device is mainly based on sensing of a specific target molecule or biomarker from human fluids,
such as blood, serum, plasma, saliva and urine, which are easy to be collected and provides
diverse sensing pathways in a less-invasive mode. Nevertheless, issues arise from poor
sensitivity and the interference biomolecules from the complex human fluids, especially red
blood cells (RBCs) from whole blood samples. For example, paper substrates are easy to be
visibly contaminated with the strong red color from RBCs, which leads to imprecise testing
results, particularly when the tests are carried out in colorimetric based assays. Additionally, the
aggregation of erythrocytes in the optical detection zone can substantially decrease signal
quality. In order to wash away the aggregates on the test area, extra washing steps are required,
which increases sample-to-answer times. Moreover, most of the clinical biochemical tests are
normally operated in the liquid portion of blood without cells, such as blood serum or plasma.
Thus, separating RBCs from whole blood is necessary and it is also crucial to elevating the
performances of sensors. Conventional separation strategies, such as mechanical forces, electroosmotic flow, dielectrophoretic techniques and magnetic interactions, can only be carried out in
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controlled central laboratories or care centers, where are equipped with sophisticated instruments
and specialized laboratory personnel.45 Thus, significant effort has been devoted into the
development of low-cost and easy-to-operated approaches, which has resulted in the rapid
development of miniaturized devices. Recently, several research groups have developed
aggregation based approaches, which allows the interception of RBCs, meanwhile enables the
separation of plasma from whole human blood samples on paper devices.46 The principle of this
method is to develop RBC aggregations, which size is too large to pass through the pores within
the fiber network of paper. For instance, a specific interaction between antibody and antigen was
utilized to trigger RBC haemagglutination inside of the fiber network of paper. However, this
method is only capable of separating RBCs from blood samples of types A, B, AB and O Rh
positive, which requires blood typing before operations. In addition, antibody immobilized
papers require critical fabrication and storage conditions, which increases costs of such devices.
Another method was developed based on introducing salt solutions to achieve the goal of
aggregating RBCs from whole blood samples. The basic mechanism is based on destabilizing
RBC suspension through suppressing the electric double layer on the surface of RBCs;
meanwhile generating of osmotic pressure, which causes RBCs to change morphologies, leading
to close packing and formation of RBC aggregations. As a result, plasma moves forward by itself
in the fiber network through capillary force.47 However, this method is difficult to be employed
into nanoparticle functionalized paper devices, since the high ionic strength from salt solutions
also induces the aggregation of nanoparticles, which leads to inaccurate signal responses and
decreased sensitivity. Recently, our research group developed Au nanostar@Raman
Reporter@silica sandwich nanoparticles, in which Raman molecules are sandwiched between an
Au nanostar and a thin silica shell.43, 48 The silica coating can stabilize nanoparticles in aqueous
solutions with high ionic strength and complex human fluids, leading to the improved stability of
the device.
In the current study, we developed a blood plasma separation unit (PSU) integrated paper
based lateral flow strip (PLFS) for carcinoembryonic antigen (CEA) detection from whole
human blood, which is an important tumor associated protein biomarker.49 In general, CEA
circulates with elevated concentrations in the fluids of patients with malignancies, such as colon
and rectal, ovary, breast, lung cancer and pancreas cancers.50 High apparent separation efficiency
and separation yield of the PSU were achieved through the employment of three layers of blood
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filtration membranes, which are designed specifically to separate plasma from whole blood
samples. The membranes in the PSU were respectively functionalized with salt (sodium
chloride), surfactant (TWEEN 20) and salt (sodium chloride). The first layer of membrane with
salt functionalization was utilized to trapping RBCs in its fiber network; while the second layer
with surfactant was used to accelerate the separated plasma to pass through the second layer. The
third layer was also immobilized with salt, which was employed to ensure that the escaped RBCs
can be trapped inside of the PSU. The three-layer construction guarantees that the PSU is capable
of separating blood plasma with high efficiency and separation rate. During CEA detection,
SERS nanoparticles (Au nanostar@Raman Reporter@silica sandwich nanoparticles) were
utilized as signal reporters, which endows high sensitivity and strong anti-interference ability to
the PSU-PLFS in whole blood samples. As a result, a LOD of 1 ng/mL of CEA was obtained,
which was below the cut-off value that presents in the blood samples of cancer patients.
Moreover, owing to the advantages of PLFS, the PSU-PLFS was capable of sensing CEA
directly from human whole blood without any sample-pretreatment, which shows a great
potential in the POC setting.

3.2 REAGENT AND INSTRUMENTS
N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and
tetraethyl orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, Na3PO4·12H2O,
Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), Bovine serum albumin (BSA),
sodium chloride, streptavidin were purchased from Sigma-Aldrich and used without further
purification. Sucrose was purchased from VWR. 4-Mercaptobenzoic acid (technical grade, 90%)
(4-MBA) was purchased from Sigma-Aldrich. 3-Triethoxylsilylpropyl succinic anhydride
(TEPSA) was obtained from Gelest Inc.
Carcinoembryonic antigen and anti-CEA antibody were procured from Sigma-Aldrich. Glass
fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), laminated cards with Hi Flow
plus cards (HF090MC100 with RK12312 Membrane (0.45 μm)), and nitrocellulose membrane
(RK13464 (0.22 μm)) were purchased from Millipore (Billerica, MA). Whole human blood was
purchased from Innovation Inc.
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3.3 PREPARATION PROCEDURES
3.3.1 Preparation of Nanoparticles

Figure 3.1. TEM images of the Au nanostar@MBA@SiO2 sandwich nanoparticles a) low
magnification and b) high magnification.

Figure 3.2. FT-IR spectrum of the carboxyl-group labeled SERS NPs. The peak at 1702 cm-1 is
assigned to the C=O stretching vibration in COOH of TEPSA.
The Au nanostars, the SERS probes and the detection antibody labelled SERS probes were
synthesized according to our previous paper.43 The preparation procedure is illustrated in Figure
3.3. Briefly, the sandwich typed SERS probes were synthesized by adding 1.0 μM of 4-MBA
into the Au nanostar suspension. Then 200 μL of 1% TEOS and 15 μL of ammonium solution
were added into the mixture with 20 min intervals. After the SERS probes were formed, the
resulting solutions were centrifuged and resolved in 500 μL of ethanoic solution. 100 μL of
TEPSA was added to the SERS probe solution and then incubated overnight to achieve the
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carboxyl-groupterminated SERS probes. The successful conjugation of carboxyl-group onto the
surface of SERS NPs was confirmed by FT-IR spectra (Figure 3.1). The carboxylgroupterminated sandwich nanoparticles were then activated by adding a PBS buffer solution
containing 50 mM NHS and 200 mM EDC and then incubated for 1 h. Subsequently, 100 μL of
1.0 mg/mL detection antibody was added, and the mixture was incubated overnight. After that,
the mixture was centrifuged and washed with a PBS buffer three times to remove excessive free
antibody. The resulting SERS probe conjugates were stored in 100 μL of eluent buffer (20 nM of
Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% sucrose) solution for future use.
The morphology and corresponding characterization can be found in our previous published
papers.43 The successful conjugation of the detection antibody onto the SERS NPs was
confirmed by the FT-IR spectrum (Figure 3.2).

Figure 3.3. Schematic illustration for synthesis of detection antibody functionalized SERS
probes.
3.3.2 Functionalization of Blood Plasma Filtration Membranes
A PSU contains three layers of blood filtration membranes (GR membrane). Each membrane
was cut with a dimension of 5.5 mm × 3 mm. Two batches of membranes were respectively
soaked and incubated in salt solution (0.154 M of sodium chloride) and surfactant solution
(TWEEN 20 (20%)) for 1 h. Then the treated membranes were dried at room temperature for 2 h.
The resulting membranes were stored in desiccators at room temperature for future use. During
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PSU assembling, each layer of membrane has an overlap of 1.5 mm with each other (as shown in
Figure 3.4).

Figure 3.4. Schematic illustration of a PSU-PLFS.
3.3.3 Preparation of Blood Plasma Separation Unit Modified Test Strip
A PSU-PLFS contains PSU, conjugate pad, nitrocellulose (NC) membrane and absorption
pad. The PSU contains three layers of blood filtration membranes, which were treated with salt,
surfactant and salt respectively. Each layer of membrane was laminated on a plastic backing with
an overlap of 1.5 mm. As shown in Figure 3.4, the top layer of membrane is modified with salt
solution, while the second layer is modified with TWEEN 20. The third layer of membrane is
also modified with salt solution, and it has an overlap of 2 mm with conjugate pad, which
ensures that the solution could migrated through PSU to the PLFS. The optical image of the side
view of a PSU is illustrated in Figure 3.5. Then the conjugate pad, NC membrane and absorption
pad were assembled following the general fabrication procedure of a PLFS. In brief, the test line
39

and control line on the NC membrane (Hi Flow plus cards HF090MC100 with RK12312
Membrane (0.45 μm)) were prepared by dispensing the solutions of capture antibody and
secondary antibody respectively with a home-made dispenser. The distance between the test and
control lines was 3 mm. The membrane was then dried at 37°C for 1 h and stored at 4°C in a dry
state. Finally, the PSU, conjugate pad, NC membrane, and absorption pad were assembled on a
plastic adhesive backing (60 mm × 30 cm) (HF000MC100). Each part overlapped 2 mm to
ensure that the solution could migrate through the entire test strip during the assay. Test strips
with a 3-mm width were cut using a paper cutter. After a PSU-PLFS was assembled, the solution
of detection antibody labelled SERS probes were loaded on the conjugate pad prior to the test.

Figure 3.5. Optical image of the side view of a PSU, which contains membrane layer-1, layer-2,
layer-3 and conjugate pad.
3.4 PERFORMANCES
3.4.1 Operation Principle
A PSU-PLFS was comprised of a blood plasma separation unit and a conventional lateral
flow test strip. The PSU was utilized to intercept RBCs inside of the unit, while the PLFS was in
charge of detecting biomarkers from the separated plasma from the PSU. As shown in Figure
3.4, the PSU contains three layers of blood plasma filtration membranes, which are placed
successively in the front edge of a PLFS. During a typical assay, 30 μL of blood sample solution
containing different concentrations of target antigen was loaded at the first filter layer of the
PSU, which was modified with salt. The salt immobilization induced the aggregation of RBCs
inside of the fiber network of the membrane; while the separated plasma containing target
biomolecules kept migrating along the PSU and then reached the second filter layer. The second
layer of filter membrane was immobilized with TWEEN 20, which expedited the separated
solution moving forward to the third filter layer. The third filter layer of PSU was also
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functionalized with salt, which guaranteed that the escaped RBCs from the first two filter layers
can still be captured inside of the PSU, realizing efficient separation of plasma from whole blood
samples. After that, 100 μL of buffer was added onto the second layer of filter. Owing to
capillary force, the separated plasma containing target antigen with running buffer migrated from
PSU to the conjugate pad of the PLFS, where the reaction between target antigens with antibody
linked SERS probes occurred. Then the resulted complexes kept moving along with the test strip
until they reached the test line and captured by capture antibody through the formation of a
sandwich

structure

(capture

antibody-antigen-detection

antibody/SERS).

The

rest

of

SERS/detection antibody conjugates migrated over the test line and captured by the control line
where the secondary antibody was immobilized. During data acquiring, the test strips were
analyzed by a portable i-Raman reader. The Raman peak intensity was in proportion to the
concentration of target antigen, which was used for quantitative work.
3.4.2 Apparent Separation Efficiency and Yield
Separation efficiency and separation yield are the two most critical factors in judging the
performances of a blood plasma separation device. In the current study, we utilized the concepts
of apparent separation efficiency (ASE) and apparent separation yield (ASY) to evaluate PSU
performances for separating RBCs from human blood sample. The processing steps of the ASE
of a PSU was illustrated in Figure 3.6. In Step 1, 30 μL of human blood sample was firstly
loaded on the first layer of filtration membrane on a PSU. After the blood plasma separation was
accomplished, a scanner was used to capture the optical images of PSUs. In Step 2, the captured
images were converted to grayscale models through the Photoshop software. In Step 3, the
images from Step 2 were inverted from black-white model to white-black model.

During

analysis, the grayscale intensity per unit area of the images in Step 3 were measured and
processed using the ImageJ software. Experimental factors, including layers of the blood
filtration membranes and the chemical functionalization of the membranes were optimized
according to the ASE of a PSU. Since a PSU contains three layers of membrane, therefore, we
utilized ASE21 and ASE31 to respectively demonstrate the ASEs between layer 1 and layer 2, and
the ASE between layer 1 and layer 3. The ASE21 and ASE31 were calculated according to
Equation (1) and (2) below:
ASE21=(Ilayer1-Ilayer2)/Ilayer1

(1)

ASE31=(Ilayer1-Ilayer3)/Ilayer1

(2)
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Figure 3.6. Optimizations and processing steps of ASE of a PSU when human blood sample was
loaded. Each blood plasma separation test was repeated three times under the same condition.
Where I represents the intensity of the grayscale in Steps 3 divided by the area of the blood
filtration membrane. The PSU was fabricated on the substrates of blood filtration membranes.
This kind of membrane was designed specifically for blood filtration through capturing RBCs in
the larger pores, while the plasma flows down into the smaller pores on the downstream side of
the membrane. Therefore, the optimizations of the filter membranes are crucial for improving the
ASE and ASY. Under the same experiment conditions, compared with one layer (Figure 3.7a),
three layers of salt treated membranes (Figure 3.7c) exhibited dramatically enhanced ASE21
from 16.1% to 91.6%, which proved that multiple layers are crucial for elevating the PSU
performances. Same conclusion can be drawn when the optical images of PSUs in Figure 3.6a
and Figure 3.6c were analyzed. Most of the RBCs can be captured and retained inside of the first
membrane layer of the three-layer membrane PSU. On the contrary, only small amount of RBCs
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can be retained at the front edge of the one-layer membrane PSU. The rest RBCs kept migrating
along on the membrane surface, which significantly contaminated the unit, leading to poor ASE.
The membrane layers from 2 to 5 were also studied through analyzing ASE12 of the PSUs. It can
be clearly seen that the ASE12 increases as the layer of membrane increases (Figure 3.8a).
Considering the ASE12 performances and cost, 3 layers of filtration membranes was chosen as
the optimal layer amount.

Figure 3.7. ASE12 and ASE23 of a PSU with different functionalization when human blood
sample was loaded.
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Figure 3.8. Experimental optimizations of the PSU. The effect of a) different layers of blood
filtration membranes; b) NaCl concentrations; c) TWEEN 20 amount on ASE12 and ASE13.
Chemical treatment is another important factor to improve ASE, especially salt treatment.
This is because that RBCs contain a weak negative charge, which contributes to stabilizing RBC
suspension in plasma. While salts can destabilize RBC suspension through generating osmotic
pressure across the RBC membrane. In addition, salt addition can suppress the electric double
layer on the RBC surfaces, which results in the shape change and close packing of RBCs, leading
to the aggregation of RBCs. Blood filtration membranes were optimized through employing
different concentrations of NaCl solutions to achieve high ASE. As descripted in Figure 3.8b,
with the increase of NaCl concentration, the ASE12 and ASE13 increase respectively. This is
because that with the increase of salt concentration, the degree of aggregation increases, which
contributes to elevated ASE. From the figure we can observe that 0.15 M of NaCl is the optimal
salt concentration, which maintained the ASE above 90%. However, owing to the formation of
the RBC aggregation in the present of salt, the generated RBC lumps might block the membrane
and slow down the rate of plasma separation. Based on this reason, surfactant was introduced to
functionalize the second layer of filter membrane for accelerating the separation progress. From
the study we found that with the increase of TWEEN 20 amount, the separation rate improved
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accordingly. Although the ASE decreased to some extent, the ASE13 of the PSU was still kept
above 90% (Figure 3.8c). The influence of surfactant was further studied through immobilizing
the entire PSU with TWEEN 20. From Figure 3.6d we can clearly see that a large amount of
RBCs migrated from layer 1 to layer 2, which indicated severely decreasing in the ASE12 and
ASE13 of a PSU (Figure 3.7d). This result showed that excessive amount of surfactant can
significant decrease the ASE even under the condition of salt functionalization. As a result, 20%
of TWEEN 20 was the chosen as the optimal amount.
Separation yield describes the percentage of extracted plasma volume from the total volume
of blood injected. In the current study, we introduced the concept of ASY for judging the PSU
performances. The ASY was calculated according to Equation (3) below:
ASY=1-(weight of RBCs absorbed on membrane (g)/weight of 30 μL of blood sample (g)) (3)
The weight of RBCs absorbed on membrane was calculated according to the weight
difference of membrane layer-1 before and after blood plasma separation. Figure 3.8 describes
the ASYs of six PSUs when 30 μL of human blood sample is loaded on each PSU. From the
figure we can see that the ASYs of PSUs approximated 30%, which indicated that the PSU was
capable of separating plasma from blood samples with outstanding efficiency and stability,
following the following PLFS tests with dramatically reduced interference from RBCs.

Figure 3.8. ASY of PSUs when 30 μL of human blood sample was loaded. The test of blood
plasma separation was repeated six times on six PSUs.

45

3.4.3 Analytical Characterization in Whole Human Blood
In order to evaluate the performances of the PSU-PLFS, whole blood sample solutions
containing different concentrations of CEA (ranging from 0 to 100 ng/mL) were measured under
optimal experimental conditions. During a typical test, 30 μL of blood sample was loaded on the
first filter layer of the PSU. After blood plasma separation, RBCs were captured inside of the
PSU, whereas plasma containing target CEA was wicked by capillary force into the PLFS, which
was functionalized with detection and capture reagents for CEA measurement. In order to
improve detection sensitivity, 100 μL of PBS running buffer was then dropped onto the second
filter layer of the PSU, which was used to drive the rest CEA molecules to migrate to the
detection zone on the PLFS. In addition, buffer introduction can also reduce non-specific
absorption on the detection area. As descripted in Figure 3.9a, the test line intensity increases
with the increasing of CEA concentration in blood samples. Moreover, most of the RBCs are
intercepted inside of the PSU; while the detection area of the PLFSs are not contaminated by
RBCs. This result indicates that the PSU-PLFS is capable of directly sensing target biomolecules
from whole blood samples. Figure 3.9b and c respectively exhibits the SERS spectra obtained
from the PLFS and the corresponding calibration curve. The regression equation was y = 1158.5x
– 239.0 with a correlation coefficient of 0.98. The detection limit of target CEA was found to be
1 ng/mL, which was estimated based on three times of signal-to-noise ratio. A linear detection
range from 5 ng/mL to 100 ng/mL was obtained and was suitable for quantitative work. The
above results implied that the developed PSU-PLFSs were working sensitively and reliably,
which attributes both to the high separation efficiency of the PSU and also to the high stability
and sensitivity of the sandwich-typed SERS probes in the complex human fluids.
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Figure 3.9. Optical images (a), SERS spectra (b) and the corresponding calibration curve of the
PSU-PLFSs for CEA detection in whole blood samples.

3. 5. CONCLUSION
A PSU has been developed for separating blood plasma from whole blood samples with high
separation efficiency and separation yield. The outstanding performance of the PSU was
achieved through employing NaCl and TWEEN 20 functionalizations on blood filtration
membranes. The treatment of the NaCl solution to first and third filter layers guaranteed that the
RBCs can be firmly intercepted inside of the PSU; while the TWEEN 20 treatment helped
accelerate separating plasma from the sticky whole blood sample. The PSU was then integrated
into a PLFS for cancer protein biomarker detection. A LOD of 1 ng/mL of CEA was obtained by
the PSU-PLFS from whole blood samples. The high sensitivity was attributed to the reduced
interferences from whole blood and the improved stability of the SERS probe in human fluids.
Moreover, the fabricated PSU can be employed in various paper devices to reduce the RBCs
interferences, showing great potential in the POC settings in remote and developing regions.
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Chapter 4: PLASMONIC CHIP-TEST STRIP IN WHOLE BLOOD
TESTING
4.1 NANOSTRUCTURED CHIP INTEGRATED TEST STRI P
The demands of point-of-care testing (POCT) have steadily risen during the past half century.
The global cost of POCTs was valued at USD 17.6 billion in 2018 and is expected to reach a
value of 36.2 billion by the end of 2025. The features of an ideal POC device are aimed at
delivering user-friendly, cost-effective and robust care near patient’s home.51 Among POC
devices, capillary flow devices are the most widely distributed and employed forms.52 The two
representative examples are pregnancy test strips and glucose test strips. The prevalence is owing
to that they are portable and user friendly, which is suitable for timely self-testing without any
professional training. Moreover, the components of test strips are made from papers, which are
low-cost and facilely storable, enabling multiple-time screenings over a specific period. The
underlying mechanism of a test strip is mainly based on sensing of a target molecule or a
biomarker. For example, a pregnancy test strip is manufactured for detecting human chorionic
gonadotrophin (hCG) in urine samples. If the hCG level attains the detectable limit of a pregnant
test strip, the optical signal from the captured bioprobe linked Gold nanoparticles (GNPs) can be
observed and used for signal readout. However, as a POC tool, there are tradeoffs. In order to
simplifying test procedures and accelerating sample screening, sensitivity and accuracy of a test
strip are sacrificed. As a result, most of the current test strips cannot be applied for early-stage
biomarker sensing, owing to that early-stage diseases always relate with trace-amount of
biomarkers. Therefore, it is of great significant to develop POC tools with enhanced
performances to address the unmet need for sensitive and reliable measurement of early-stage
biomarker, which is beneficial to providing timely diagnosis and properly management and
finally increasing patient survival rates.
Optical and electrochemical techniques have been widely employed in test strips. Sensing
signals are generated through interfacing biological recognition events in test strips and then
transmitted through transducers to a signal processor for data analysis. Integrating nanomaterials
into test strips is an effective way to improve detection sensitivity.52c It is because these
nanomaterials possess unique properties, such as inherent large surface area, excellent
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biocompatibility, outstanding conductivity and catalytic ability, which help amplify the
transduction of biorecognition events, retain bioactivity of biomolecules and accelerate signal
transduction, leading to an elevation in detection sensitivity. GNP is the most representative
signal tag that used in test strips, owing to the fact that GNPs are stable, easy to synthesize and
can provide strong contrast with the white background of a test strip. Moreover, the optical
properties of GNPs can be easily tuned through changing their size and morphologies, which
helps amplify response signal. Besides GNPs, silver nanoparticles,53 magnetic nanoparticles,54
fluorescent based quantum dots and organic dyes and fluorescent nanoparticles55 have also been
employed as signal reporters to elevate the performances of test strips. However, most of the
above mentioned sensors fail in real-world sample applications due to non-specific interferences
and strong color interference from sample matrices, especially from whole blood samples. In
order to overcome this issue, sample pre-treatment, sample dilutions and introducing signal
amplification techniques are always required. As a result, the involved complicate experimental
procedures limit their applications in POC uses.
Surface-enhanced Raman scattering (SERS) is a powerful technique that possesses ultrasensitivity by amplifying the Raman scattering signal by orders of magnitude if a molecule is
associated to the surface of a rough metal or plasmonic nanomaterial.56 This improvement is
based on the coupling of EM field enhancement of nearby noble metal nanomaterials, which
leads to the formation of “hot spots” for SERS enhancement. The tremendous enhanced Raman
responses make SERS technique attractive for ultrasensitive sensing.57 In addition, SERS
technique owns “fingerprint” feature to elevating the anti-interference resistance to nonspecific
molecule, which is well-suited for specifically targeting biomolecules from complex sample
matrices. Gold and silver are the most representative SERS-active nanomaterials. They can be
integrated into sensors as nanoparticles, patterned nanostructures or sharp metal tips. In order to
maximize the effect of enhancement, the size and morphology of SERS-active nanomaterials
have been precisely controlled. Recently, our group developed a three-dimensional (3D)
plasmonic nano-architecture immunosensor for cancer biomarker sensing.40 A 3D confined
plamonic field was created by coupling the gold triangle nanoarray with the sandwich-typed
SERS probe, which generated a high density of “hot spot” for ultrasensitive detection. In
addition, the gold triangle nanoarray chip can concentrate the plasmonic field and create hot
spots near the sharp tips, leading to dramatically improvement in SERS signal and detection
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sensitivity. As a result, this immunosensor was capable of detecting cancer protein biomarker
directly in clinical blood plasma samples. Although the immunosensor exhibited advantages of
shorter detection time compared with the standard ELISA method, it is difficult to be utilized as
a POC tool, since expert personnel is still required to operate the test.
In the current study, we designed a 3D plasmonic nano-architecture functionalized lateral
flow test strip, which can sustain the property of a POC tool, at the same time, realize
ultrasensitive measurement of biomolecules in complex human fluids. Similar with the above
mentioned gold triangle nanoarray chip, the proposed gold nanopyramid array chip in this study
also presents sharp tips, which is expected to provide high sensitivity for SERS sensing. During
the device fabrication, the capture antibody was immobilized on the chip surface; while the
SERS gold nanostar@Raman molecules@silica sandwich nanoparticles were labeled with
detection antibody. In the present of target molecule, the detection antibody linked SERS
nanoparticles are captured over the gold pyramid nanoarray, forming a confined 3D plasmonic
field, leading to the significantly enhanced electromagnetic field in intensity and in 3D space.
During the detection, no extra washing operations were required owing to the present of a
surfactant bridge proposed in this study. The surfactant bridge was built across the chip surface
to reduce the surface tension, which ensures the sample fluid can flow smoothly across the entire
device. Compared with the signal from SERS nanoparticles on NC membrane, the SERR signal
from the 3D plasmonic nano-architecture was improved significantly. As a result, the developed
plasmonic chip integrated test strip was capable of detecting TBI protein biomarker directly from
the plasma samples of clinical patients, showing great promises for detection of biomarkers in
POC applications.
4.2 MATERIALS AND METHODS
4.2.1 Reagents and Materials
4-Mercaptobenzoic acid (technical grade, 90%) (4-MBA) was purchased from Sigma-Aldrich.
3-Triethoxylsilylpropyl succinic anhydride (TEPSA) was obtained from Gelest Inc.
Nhydroxysuccinimide (NHS), 1-ethyl-3-(3-(dimethylamino)-propyl) carbodiimide (EDC), 11mercaptoundecanoic acid (MUA), 11-mercapto-1-undecanol ethanolic (MU) and tetraethyl
orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, sucrose, Na3PO4·12H2O,
Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), Na3PO4·12H2O, BSA (bovine serum
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albumin) and sodium chloride were purchased from Sigma-Aldrich and used without further
purification. Sucrose was purchased from VWR. S-100β and anti-S-100β antibody were
procured from Sigma-Aldrich. S-100β ELISA Kits were purchased from R&D System. The
blood plasma was purchased from US Biological Life Science (P4252-56 Plasma, Human, IgG
Free). Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), laminated cards
with Hi Flow plus cards (HF090MC100 with RK12312 Membrane (0.45 μm)), and nitrocellulose
membrane (RK13464 (0.22 μm)) were purchased from Millipore (Billerica, MA). Quartz slides
were purchased from Fisher Scientific Inc. Polystyrene (PS) beads (500nm diameter) were
purchased from Thermo Scientific. Clinical blood plasma samples were collected from TBI
patients and provided by WVU medical school.
4.2.2 Instruments and Characterization
All Raman spectra were acquired with a portable B&W Tek i-Raman Plus. Fourier transform
infrared (FT-IR) spectra were obtained under the attenuated total reflection (ATR) mode with
Thermo Nicolet 6700 spectrometer. The nanoparticles were characterized with a transmission
electron microscope (TEM, JEOL JEM-2100F) at an acceleration voltage of 200 kV. UV−visible
absorption spectra were obtained with a Shimadzu UV-2550 spectrometer. Titanium and gold
metals were deposited by e-beam evaporator (Kurt J Lesker). A scanning electron microscope
(JEOL-JSM-7600F) was used to image the gold nanopyramid array. Optical characterization of
gold nanopyramid array was done using an Ocean Optics 4000 spectrometer and DT-MINI-2GS.
4.3 PREPARATION PROCEDURES
4.3.1 Synthesis of Gold Nanopyramid Array Chip and Functionalization of Capture Antibody on
Chip
Nanosphere lithography fabrication technique was used to fabricate the nanopyramid
structure. Initially quartz slides were cut in the form of chips with dimensions around 1cm x
1cm. The chips were cleaned in acetone, methanol and DI water for 5 min in each respectively.
The cleaned quartz chips were immersed in acid piranha at 90 °C for 1 h, which makes the quartz
surface hydrophilic. Further, the chips were rinsed in DI water and 500nm diameter polystyrene
(PS) beads were dip-coated to form a Hexagonally Closed Pack (HCP) monolayer. The
monolayer is allowed to dry for 10min. Later, a 5 nm titanium film was deposited followed by
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250 nm gold film using e-beam evaporator. The metal deposits on to the quartz through the
interstitials spaces of nanospheres to form pyramid shape. The polystyrene beads were removed
by ultrasonication of chips in methanol, leaving the gold nanopyramids on the quartz substrate.
Due to the titanium adhesive layer, the gold nanopyramids were intact on the quartz substrate.
The fabricated chip was cleaned by successive immersion in ethanol and D.I. water for 10
min, respectively. The cleaned gold films were incubated overnight in a solution containing 100
mM MUA/100 mM MU and then washed using ethanol and D.I. water, respectively. The
successful conjugation of MUA/MU onto the gold film was confirmed by FT-IR spectra (Figure
4.1). The resulting MUA/MU modified chip was activated by immersion in a solution containing
50 mM NHS/200 mM EDC in a PBS solution. The chip was incubated overnight in a PBS
solution containing 1 mg/mL of anti-S-100β. Successful conjugation of capture antibody onto the
chip was confirmed by FT-IR spectra (Figure 4.2), in which the peak at 1541 cm-1 indicated the
N–H bending. After immobilization of the antibody, the chip was successively rinsed with D.I.
water and PBS solution to remove free and excess antibody molecules.

Figure 4.1. FT-IR spectra of MU/MUA functionalized chip. The peak at 1705 cm-1 peak is
assigned to the C=O stretching vibration.
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Figure 4.2. FT-IR spectra of the capture antibody functionalized chip. The peak at 1541 cm-1
corresponds to the N-H bending in the antibody.
4.3.2 Functionalization of Surfactant Bridge on Chip Surface
The surfactant bridge contains two components: TWEEN 20 and glucose. 1 μL of TWEEN 20
was dropped on and then spread evenly on the surface of the capture antibody immobilized
plasmonic chip. After that 0.01 g of glucose was sprinkled on the TWEEN 20 covered chip
surface. The surfactant bridge functionalized chip was stored in dry ambient for 0.5 h and then
stored at 4°C for further use.
4.3.3 Synthesis of Nanoparticles and Conjugation with Detection Antibodies.
The Au nanostars, the SERS probes, and the nanoparticles conjugated with detection
antibodies were synthesized according to our previous paper.58 Briefly, the Au nanostar@Raman
molecule@Silica sandwich SERS probes were synthesized by adding 1.0 μM Raman molecules
into the Au nanostar suspension. Then, 200 μL of 1% TEOS and 15 μL of ammonium solution
were added into the mixture, successively. After the SERS probes were formed, the resulting
solutions were centrifuged and resolved in 500 μL of ethanoic solution. The Au nanostars were
coated with a 2−3 nm thick silica layer on the outer surface. Next, 100 μL of TEPSA was added
to the SERS probe solution and then incubated overnight to achieve the carboxyl-group
terminated SERS probes. The conjugation of carboxyl-group onto the surface of SERS
nanoparticles was confirmed by FT-IR spectra (Figure 4.3). The carboxyl-group terminated
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sandwich nanoparticles were then activated by adding a PBS buffer solution containing 50 mM
NHS and 200 mM EDC and then incubated for 1 h. Subsequently, 100 μL of 1.0 mg/mL
detection antibody was added, and the mixture was incubated overnight. The successful
conjugation of detection antibody onto SERS nanoparticles was confirmed by the FT-IR spectra
(Figure 4.4). After that, the mixture was centrifuged and washed with a PBS buffer three times
to remove excessive free antibody. The resulting SERS probe conjugates were stored in 100 μL
of eluent buffer (20 nM of Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10%
sucrose) solution for future use. The corresponding characterizations can be found from Chapter
2 in this dissertation.

Figure 4.3. FT-IR spectra of the carboxyl-group modified SERS probe. The peak at 1709 cm-1
peak is assigned to the C=O stretching vibration in COOH of TEPSA.
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Figure 4.4. FT-IR spectra of the detection antibody functionalized SERS probe. The peaks at
1666 and 1550 cm-1: correspond to the N-H bending in the antibody.

4.3.4 Preparation of Chip-Test Strip

Figure 4.5. Schematic illustration of the operation principle of chip integrated PLFS.
Figure 4.5 shows the schematic diagram of the fabricated chip-PLFS, which consists of five
components: a sample pad, a conjugate pad, two nitrocellulose membranes (NC membrane), a
gold nanopyramid array chip and an absorption (or wick) pad. All the components were mounted
on a common backing layer (typically an inert plastic, e.g., polyester). The sample pad was
saturated with a Tris-HCl buffer (pH 8.0) containing 0.23% Triton X-100 and 0.05 and 0.15 M
NaCl. The pad was then dried at 37 °C for 2 h and stored in a desiccator at room temperature
(RT). Then, the surfactant bridge covered capture antibody labeled chip was placed between two
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NC membranes. The dimension of each NC membranes was 1.1 cm × 0.3 cm. The detection
antibodies modified SERS probes were dropped onto the conjugate pad. Finally, all the five
processed components were assembled onto a plastic adhesive backing layer. The paper
components were overlapped with 2 mm to ensure that the solution was able to flow through the
whole strip. Each paper component was cut to be 3 mm wide by a paper cutter (Swingline 12 in.
ClassicCut Lite Trimmer). Before testing, 5 μL of detection antibody linked SERS probes was
loaded onto the conjugate pad. During testing, 100 μL of sample solution containing a certain
concentration of target biomolecule was dropped on the sample pad.
4.4 RESULTS AND DISCUSSION
4.4.1 Characterizations of Gold Pyramid Nanoarray

Figure 4.6. a) TEM images of the gold nanostar@MBA@SiO2 sandwich nanoparticles; SEM
images of b) large-area view and c) enlarged view of the gold nanopyramid array, and d) UV-Vis
reflection spectra of the gold nanopyramid array.
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The synthesized SERS nanoparticles contain a core of gold nanostar and a silica shell; while
the Raman molecules are sandwiched between the gold core and the silica shell. The metal core
is able to amplify the SERS signal; while the silica shell can protect the nanoparticles away from
the interferences of surrounding environment. In addition, numerous of Raman molecules can be
concentrated inside of the silica shell of one single SERS probe, which can significantly improve
sensitivity. Figure 4.6a, exhibits the TEM image of the gold nanostar@MBA@SiO2 sandwich
nanoparticles. It can be clearly seen that the gold nanostars exhibit a star shape and possess sharp
tips, which contributes to remarkable signal amplification. A 4~5 nm thick SiO2 layer can also be
observed from the TEM image, which indicates that the silica shell was successfully coated onto
the nanoparticles. Figure 4.6b and c show the SEM images of the gold nanopyramid arrays. The
gap between the adjacent pyramid corners in the gold pyramid nanoarray was about 40 nm,
which enables the coupling of LSPR. The UV-Vis reflection spectra from Figure 4.6d further
confirms that the gold nanopyramid array is capable of coupling LSPR, generating a high density
of hot spots for the SERS enhancement.
4.4.2 Operation Principle
The prepared plasmonic chip-PLFS contains dry reagents which can be activated by applying
a fluid sample (Figure 4.5). Once the sample solution is dropped onto the sample pad of the
chip-PLFS, it will flow automatically from sample pad to conjugate pad by capillary force. On
conjugate pad, an interaction between target protein and detection antibody linked SERS probes
occurs. The resulting complex continues to move along with the chip-PLFS until it reaches the
boundary between the NC membrane and the plasmonic chip. With the help of surfactant bridge,
the sample solution can migrate smoothly across the chip surface. At the same time, the
surfactant bridge starts to dissolve and the capture antibody labeled chip surface is exposed for
capturing the above obtained bio-complex. Figure 4.7 shows that the surfactant bridge is
dissolved 2 min after running buffer is added, indicating that the fluid flows smoothly across the
device, meanwhile the surfactant bridge doesn’t block signal acquisition from chip surface.
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Figure 4.7. Optical images of a chip-PLFS before and after the sample solution is loaded.
As a result, a sandwich-typed structure of SERS probe/detection antibody-protein-capture
antibody is formed on the plasmonic surface, leading to the formation of a confined 3D
plasmonic field for generating ultrasensitive SERS signal. The operation principle is illustrated
in Figure 4.8. A portable Raman spectrometer is employed to record the SERS signal from the
plasmonic chip surface. Under excitation by a 785 nm laser, the SERS signal is generated from
the MBA (Raman reporter) molecules inside of the captured SERS probes. The obtained SERS
signal is in proportion to the concentration of target protein, which is used for quantitative work.

Figure 4.8. Schematic illustration of the reactions on chip integrated PLFS.
4.4.3 Comparison of Raman Signal on Different Substrate
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Figure 4.9. Comparison of SERS signal on Au pyramid, planar Au chip and NC membrane
respectively.
In order to verify the substantial improvement in SERS signal, a comparison study was
conducted. Three configurations of plasmonic hierarchical architecture were employed as SERS
substrates, including SERS NPs on Au nanopyramid array chip, SERS NPs on planar Au chip
and SERS NPs on NC membrane. From Figure 4.9 we can find that the SERS NPs/Au
nanopyramid array chip exhibits the highest SERS signal at the specific Raman peak of 1084 cm1

, while the signal from SERS NPs/NC membrane is much less efficient. This signal

improvement is endowed from the high density of hot spots in the 3D hierarchical architecture of
the SERS NPs/Au nanopyramid array chip. In addition, both of gold nanostars are gold
nanopyramid array possess LSPR bands at ~785 nm, which are overlapped with the wavelength
of excitation laser, leading to dramatically improvement in sensing performance. This result also
allows us to investigate the effects of the plasmonic chip (Au planar chip and Au nanopyramid
array chip) and the non-plasmonic substrate (NC membrane) on the performance of the SERSPLFS.
4.4.4 Optimizations
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Figure 4.10. Optimization of the experiment conditions for chip-PLFS. a) Effect of the chip
displaying position on the S/N ratio of chip-PLFSs, b) effect of SERS probe volume on the S/N
ratio, c) effect of effect of the amount of capture antibody modified on chip on the S/N ratio.
In order to elevate the performance of the chip-PLFS, human IgG and anti-IgG antibody was
chosen as models to optimize the device. 10 ng/mL of human IgG was used as target molecules
in all of the following optimization experiments. The incubation time of detection antibody with
target antigen, and capture antibody with target antigen significantly influences the binding
efficiency, as well as the sensitivity. Therefore, the binding timing and extent need to adjusted,
which can be implemented through optimizing the displaying positions of plasmonic chip in test
strip. The displaying chip position means the distance between the front boundary sides of the
plasmonic chip with the conjugate pad. Figure 4.10a reveals that the S/N ratio of the SERS peak
increased with the growing distance of the plasmonic chip away from the conjugate pad until the
distance reached 11 mm, which means when the distance is below of 11 mm, the binding time
between detection antibody and antigen is not enough. Further increasing the distance led to a
decrease in the binding time between the detection antibody/antigen complexes with the capture
antibody, since most of the biomolecules were immediately adsorbed by the wicking pad after
they arrived at the chip surface. As a result, the optimal displaying distance of the chip in test
was 11 mm away from the conjugate pad. Another two important parameters which affect the
capturing ability of signal reporters are the amount of nanoparticle linked detection antibody and
the concentration of capture antibody on the chip surface. From the S/N ratios (Figure 4.10b and
c), the optimal concentration of SERS probe was 5 μL; while 1.5 mg/mL of capture antibody was
the best amount.
4.4.5 Measurement of S-100β in Buffer
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Figure 4.11. SERS spectra (a) and calibration curve (b) of chip-PLFSs with MBA as Raman
reporter for detection of s-100 β in PBS buffer.
In order to evaluate the performances of the chip-PLFS, buffer solutions containing different
concentrations of s-100β (ranging from 0 ng/mL to 100 ng/mL) were measured under optimal
experimental conditions. During a typical test, 100 μL of sample solution was loaded on the
sample pad of the chip-PLFS. After 30 min reaction, the SERS signal of the chip-PLFS was
recorded by a portable Raman spectrometry. Figure 4.11a and b respectively exhibits the SERS
spectra obtained from the plasmonic chip and the corresponding calibration curve. The
calibration curve was obtained by plotting the SERS peak intensity at 1084 cm−1 from MBA as a
function of the logarithmic concentration of s-100β. The regression equation was y = 184.3x +
570.5 with a correlation coefficient of 0.93. The detection limit of this device for s-100β in
running buffer was found to be 1 pg/mL, which was estimated based on three times of signal-tonoise ratio. Compared with the results from the previously reported SERS-test strips, the
proposed chip-PLFSs exhibited a 20 times improvement in detection sensitivity, which is
endowed from the high density of hot spots in the 3D hierarchical architecture. In addition, both
gold nanostars are gold nanopyramid array possess LSPR bands at ~785 nm, which are
overlapped with the wavelength of excitation laser, leading to dramatically improvement in
sensing performance. A linear detection range from 10 pg/mL to 100 ng/mL was obtained and
was suitable for quantitative work.
4.4.6 Measurement of s-100β in Clinical Blood Plasma Samples
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The above results indicated that the developed chip-PLFSs were working sensitively and
properly. In order to further verify the accuracy of the device, chip-PLFSs were employed to
examine the s-100β level from plasma samples taken from six TBI patients. Commercial
standard ELISA Kit was used as a comparison. Before testing clinical samples, the chip-PLFSs
were calibrated with known concentrations of s-100β, which was spiked into 80% of commercial
blood plasma respectively (P4252-56 Plasma, Human, IgG Free). The baseline concentration of
s-100β in blood plasma matrices was estimated by an s-100β ELISA kit. No obvious signal can
be observed from the blood plasma sample, which indicates that the baseline concentration of s100β in blood plasma is below the detection limit of the ELISA kit, showing no interference on
s-100β sensing.

Figure 4.12. SERS spectra (a) and calibration curve (b) of chip-PLFSs for detection of s-100 β in
80% of blood plasma.
Figure 4.12 shows the SERS spectra of the 3D hierarchical architecture integrated test strips
in the presence of various concentrations of s-100 β in 80% blood plasma. From the SERS
spectra we can see that the intensity of the SERS peak at 1084 cm−1 gradually increased with an
increase in the s-100 β concentration. The SERS peak intensity (y) versus the s-100 β
concentration (x) was fitted as y = 175.1x + 437.3 with the relative coefficient (R2) of 0.96,
showing a linear detection range from 0.1 to 100 ng/mL, achieving a LOD of 5 pg/mL. The
calibration curve indicated that the developed chip-PLFSs can work for s-100 β detection in
blood plasma. After calibration, the developed chip-PLFSs were employed for detection of s-100
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β from clinical samples of patients with TBI. The clinical samples were also examined by the
standard ELISA method. Figure 4.13 exhibits the result comparison from the chip-PLFSs and
the ELISA kit. The results showed that the results from chip-PLFSs were comparable from the
ones from ELISA kits, suggesting that the proposed chip-PLFSs were capable of sensing s-100 β
in clinical samples. Moreover, compared with ELISA kit, the proposed chip-PLFSs provide
significant advantages, in terms of shorter sensing time (30 min vs several hours), simplified test
procedures and inexpensive test.

Figure 4.13. S-100 β concentrations in clinical blood plasma samples, which were measured by
ELISA and the chip-PLFS, respectively.
4.4.7 Measurement of s-100β in Whole Blood Samples
In Chapter 3, we successfully detected target protein from whole blood samples by
employing a PSU integrated paper test strip. In the current study, in order to further verify the
performances of the chip-PLFSs, we challenged to test s-100β from whole blood samples
through modifying a PSU into the developed chip-PLFS. During a typical assay, 30 μL of blood
sample solution containing different concentrations of s-100β (ranging from 0 to 100 ng/mL)
was loaded on the first filter layer of the PSU. After blood plasma separation, RBCs were
blocked inside of the PSU, while the separated plasma containing target s-100β was wicked into
the chip-PLFS, which was functionalized with capture and detection reagents for s-100β
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measurement. 100 μL of PBS running buffer was then dropped onto the second filter layer of the
PSU, which was used to drive the rest s-100β molecules to migrate to the detection zone on the
chip-PLFS; meanwhile, buffer introduction can also reduce non-specific absorption on the
detection area. As descripted by the SERS spectra in Figure 4.14a, the intensity of the typical
Raman peak at 1080 cm-1 increases with the increasing of s-100β concentration in blood
samples, which indicates that the PSU integrated chip-PLFSs are working properly in whole
blood samples. Figure 4.14b shows the corresponding calibration curve. The regression equation
was y = 20.7x + 578.9 with a correlation coefficient of 0.95. The detection limit of this device
for target s-100β was found to be 50 pg/mL, which was estimated based on three times of signalto-noise ratio. A linear detection range from 0.1 ng/mL to 100 ng/mL was obtained and was
suitable for quantitative work. The above results implied that the developed PSU-chip-PLFSs
were working sensitively and reliably, which attributes both to the high separation efficiency of
the PSU and also to the high sensitivity and anti-interference ability of the developed 3D
plasmonic device.

Figure 4.14. SERS spectra a) and calibration curve b) of PSU-Chip-PLFSs with MBA as Raman
reporter for detection of s-100 β in whole blood samples

4.5 CONCLUSION
In summary, an ultrasensitive plasmonic chip integrated test strip was developed for protein
biomarker detection. In the presence of target protein, a 3D hierarchical architecture can be
formed on sensing area, which forms a 3D confined plasmonic field to generating high densities
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of hot spots, leading to a significant enhancement in SERS signal. As a result, the developed
chip-PLFSs showed a 20-time improvement in detection sensitivity for target protein in running
buffer compared with the results from the conventional SERS test strip. In addition, the chipPLFSs possessed anti-interference ability towards complex human fluids and were capable of
sensing s-100β directly in clinical blood plasma samples and whole blood samples. The test
results were comparable with that from the standard ELISA method, showing great promises as a
POC tool in real applications.
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Chapter 5: NEAR-INFRARED FLUORESCENCE IN BLOOD PLASMA
TESTING
5.1 CIRCULATING BIOMARKER: MIRNA-34
Circulating microRNAs (miRNAs) are a class of cell-free miRNAs, which are stably present
in the body fluids of many mammalian including human beings.59 Since the first description in
the 1940s, these circulating nucleic acids were found to exhibit disease-related alternations.60 For
example, increased levels of plasma circulating nucleic acids have been detected in a number of
diseases even at a very early stage, such as cancers, stroke and autoimmune disease.61
Circulating miRNAs are existing in many human fluids, such as serum, plasma, saliva, urine and
bronchoalveolar lavage fluid, which provides diverse sensing pathways in a less-invasive mode.
In addition, compared with detecting a low abundant of other biomarkers (e.g. proteins or tumor
tissues), high sensitivity can be relatively feasibly achieved through detecting circulating
miRNAs by the powerful qRT-PCR and microarray techniques. The unique features of
circulating miRNAs, including high sensitivity, specificity and less-invasive manner expand their
clinical importance in diseases diagnosis and monitoring.62 Up to now, around 100 circulating
miRNAs have been identified as biomarkers which can reflect the early existence and the
progression status of diseases.63 However, in order to detect circulating miRNAs with the current
technologies, the extraction and purification procedures of circulating miRNAs from these
human fluids are required. Although the demands of high specificity and sensitivity can be
fulfilled, the complicated procedures and sophisticated instruments hindered these techniques to
be operated only under the controlled laboratory environment.
Fluorescence techniques have been extensively applied in biological sensing, cell screening
and clinical diagnosis owing to their low detection of limit and ability of visualization of events
related disease progression with short-time data acquisition.27a,

27b, 64

The performances of

fluorescence techniques are largely dependent on the properties of the employed fluorophores.
When choosing or designing a fluorophore, several aspects should be taken into consideration,
including excitation and emission nature, luminescence intensity, photostability and
biocompatibility. The use of near-infrared fluorophores (NIRF) is a promising approach for
biomedical sensing in biological specimens. It can reduce the damage of biological samples and
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avoid the photobleaching and background interference when visible fluorophores (VisF) are
utilized. This is because that due to reduced absorbance and minimal scattering, the NIR
radiation possesses high penetration ability towards tissues and biological matrices.29,
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Meanwhile, the NIR wavelengths falls within the biological windows with low background
fluorescence signals, which provides elevated signal-to-noise ratio.30 These unique features offer
great opportunity to employ NIRFs in biological fields. Nevertheless, in contrast to VisFs, the
major shortcoming of NIRFs is limited intense. Additionally, its biocompatibility and
photostability should also be concerned during the design of a NIRF probe.
Dye-encapsulated silica nanoparticles appear to be an effective alternative to achieve the
goals. The superior properties of such nanoparticles include amplified signal, outstanding
photostability, water-solubility and viability of surface modification.31, 66 For example, the silica
layer enables a large number of dye molecules to be encapsulated inside of one single silica
nanoparticle, which can dramatically magnify its luminescence signal. In addition, the external
silica layer protects the dyes from the surrounding matrix or other environment, which minimizes
the photobleaching phenomena and increases its photostability. Moreover, silica possesses
flexible routes for surface modifications with various types of functional groups (e.g. –NH2, COOH, -SH), which allows its conjugation with different biomolecules during bioassays. To
date, many promising NIRF dye-encapsulated silica nanomaterials have been reported with
improved stability and detection sensitivity in biological applications.67 However, the main
challenges of current applications comprise obstacles concerning the tedious operations, lack of
sophisticated instrument and trained personnel in less-industrialized areas or in-field
measurements. To address this issue, many attempts have been made to develop simple and lowcost point-of-care (POC) devices especially paper-based test strips.68 Compared to conventional
test devices, paper test strips provide outstanding advantages including fast testing time, low cost,
simple design and operation, which is attractive as a POC tool.12, 69
In this study, we synthesized NIRF (cyanine 7 amine) dye encapsulated silica nanoparticles
and integrated the nanomaterials as signal reporters into a lateral flow test strip. Compared with
previous published methods for miRNA detection (summarized in Table 5.1), the present
method can realize the direct detection of target miRNA in blood plasma samples without any
sample pretreatment and complicated operation steps. It is because that the developed NIRF test
strips take the advantages both from NIRF dyes and test strips, which avoids the issues of the
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interference problems from visual range, meanwhile holds the promises in POC and in-field
applications. In addition, after loading the sample solution onto the NIRF test strips, the test
results can be read out directly with a portable fluorescent reader within 40 min. In the current
study, circulating miRNA-34a was employed as the target molecule, owing to its potential in
clinical applications as prognostic/predictive biomarkers in various forms of cancers, metabolic
diseases and neurological diseases.70 Moreover, we also synthesized two VisFs encapsulated
silica nanoparticles and compared their performances with that from the NIRF test strips. As a
result, the NIRF test strips showed substantial improvement in detection sensitivity when target
miRNAs were present in blood plasma specimens.
Table 5.1. Comparison of the present study with previous research from publications for miRNA
detection.
Methods

Target miRNA

LOD

Linear Range

Conventional

Northern

[1] miRNA-171 and

pM

N/A

Ref 71

Method

Blotting

miRNA-319;

QT-PCR

[2] let-7a, miRNA-16,

nM-fM

N/A

Ref 72

pM-fM

N/A

Ref 73

nM-fM

[8] 0.075 to 10

Ref 12,

nM; [9] 8 pM to

38, 74

miRNA-20, miRNA-21,
miRNA-22;
[3] miRNA-39, miRNA-54,
miRNA-238;
[4] hsa-miRNA-21, hsamiRNA-181b, hsa-miRNA106a
Microarray

[5] chsa-miR-451 et al; [6]
Let-7d et al; [7] Let-7i

Optical

Colorimetric

[8] miRNA-215; [9]

Method

Method

miRNA-224; [10] 0.1 pM

75 nM; [10] 0.20
fM to 10 pM
Fluorescence

[11] let-7; [12] let-7; [13]

Method

miRNA-21, miRNA-125b,

pM-aM

[11] 0.1 nM to 0.1

Ref 75

fM & 0.1 μM to

68

miRNA-96

0.1 nM; [12] 50–
200 pM [13] N/A

SPR

[14] miR-21; [15] miRNA-

pM

[14] 10 pM-μM;

21

Ref 76

[15] 5 pM to
100 nM

Electrochemic

Amperometric

[16] let-7a; [17] miRNA-21;

al Method

Method

[18] miR-21

fM-aM

[16] 10 fM−1

Ref 77

nM; [17] 0.1 pM1 nM [18] 10 fM
to 10 nM

Impedimetric

Present

Fluorescent

method

Method

[19] miRNA-34a; [20] let-

[19]

[19] 0 to ~147

7b

28.1 pM

pM; [20] 2.0 fM

[20] fM

and 2.0 pM

50 pM in

100 nM-0.1 nM

MiRNA-34a

Ref 78

50% of
blood
plasma

5.2 MATERIAL AND INSTRUMENTATIONS
N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and
tetraethyl orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, Na3PO4·12H2O,
Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), Na3PO4·12H2O, Bovine serum
albumin (BSA), sodium chloride, streptavidin were purchased from Sigma-Aldrich and used
without further purification. Sucrose was purchased from VWR. 3-Triethoxylsilylpropyl succinic
anhydride (TEPSA) was obtained from Gelest Inc.
Silica nanosphere (60 nm) was purchased from Nanocomposix, Inc. Cyanine 7 amine
(NIRF) was purchased from Lumiprobe, Alexa FluorTM 633 (VisF-1) was purchased from Life
technologies, Rhodamine 6G (VisF-2) was purchased from Fluka. Blood plasma was purchased
from US Biological Life Science (P4252-56 Plasma, Human, IgG Free).
Target miRNAs were purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and
have the following sequences:
Target miRNA-34a: 5’-UGG CAG UGU CUU AGC UGG UUG U -3’
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Detection probe (probe 1): 5’-/NH2/-AAA ACA ACC AGC-3’
Capture probe (probe 2): 5’-ACA CTG CCA-/Biotin/-3’
Control probe (secondary probe): 5’-/Biotin/-GCT GGT TGT TTT AAA/-3’
Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), laminated cards
(HF000MC100), and nitrocellulose membranes (HFB18004 and HFB 24004) were purchased
from Millipore (Billerica, MA).
E/D cPOC fluorescent readers: (365 nm/615 nm; 632 nm/650 nm; 750 nm/755 nm) were
purchased from LRE Medical GmbH.
5.3 PREPARATION PROCEDURES
5.3.1 Preparation of Dye Encapsulated Silica Nanoparticles

Figure 5.1. SEM images of a) commercial silica beads and b) synthesized NIRF nanoparticles.
The encapsulation of dyes was accomplished by coating of commercial silica nanospheres
with an outer layer containing fluorescent dyes. In brief, 50 μL of 100 μg/mL of fluorescent dye
was mixed with 50 μg/mL of commercial silica nanospheres in 10 mL of ethanol solution. The
obtained mixture was kept stirring for 20 min. Then 10 μL of TEOS and 10 uL of 28% ammonia
hydroxide were added into the solution with 20 min intervals. All of the above reactions were
carried out under darkness. After overnight incubation, the reaction between TEOS and ammonia
hydroxide leads to the formation of a silica shell on the dye-nanoparticle surface. The resulting
nanoparticles were collected by washing and re-dispersion steps through centrifuging in ethanol
solution for several times. The final nanoparticles were re-suspended in 1 mL of ethanol solution
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for future use. This encapsulation method guarantee the uniformity of the dye encapsulated silica
nanoparticles and has potential to permit the synthesis of dye encapsulated silica nanoparticles
with precisely tunable sizes through adjusting the amount of TEOS and ammonia hydroxide.
Figure 5.1a and b show the SEM images of the commercial silica beads and the synthesized
NIRF encapsulated silica nanoparticles respectively. From Figure 5.1b we can see that the NIRF
nanoparticles were well dispersed and showing spherical morphology, which demonstrated that
the silica outer layer was uniformly coated onto the silica core. Particle sizes were determined by
Nano Measurer. The average particle sizes of the commercial silica beads and the NIRF
nanoparticles were found to be 59.7 ± 2.0 nm and 62.5 ± 2.6 respectively. The increase in size
reveals that the thickness of the silica outer layer was at ~ 5 nm.
5.3.2 Labeling Detection DNA with Nanoparticles
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Figure 5.2, FT-IR spectra of the carboxyl-group functionalized silica nanoparticles. The peak at
1736 cm-1 peak is assigned to the C=O stretching vibration in COOH of TEPSA.
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The preparation of labeling DNA-NH2 with NIRF encapsulated nanoparticles followed the
previously reported method.79 The obtained 1 mL of silica coated NIRF nanoparticles were
mixed with 20 μL of TEPSA. The mixture solution was incubated overnight to achieve carboxyl
group-terminated NIRF nanoparticles. The immobilization of carboxyl group onto the surface of
silica was verified through FTIR spectra (Figure 5.2), in which the peak at 1736 cm−1 indicated
its successful linking. After washing with ethanol and D.I. water for several times, the resulting
nanoparticles were re-suspended in 0.5 mL of the solution containing 50 mM NHS and 200 mM
EDC. After incubation for 2 h, the COOH group was activated. 50 μL of 20 μM ssDNA (amine
group labeled detection DNA) solution was then added into the mixture. After overnight
incubation, the solution was washed with a buffer solution (PBS containing 0.1% of BSA) for
three times. The resulting nanoparticles were finally suspended in 200 μL of Eluent buffer (20
nM of Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% sucrose) and stored
under 4 °C for future use. The schematic representation of the synthesis procedure of the NIRF
nanoparticle is shown in Figure 5.3. The successful labeling of amine group linked detection
DNA onto silica was examined and proved by FTIR spectra. As shown in Figure 5.4, the peaks
at 1655 cm-1 and 1550 cm-1 were assigned to the N-H bending from the amine group linked
detection DNA.

Figure 5.3. Schematic illustrations of NIRF encapsulated silica nanoparticles synthesis and
labeling detection DNA probe with the NIRF encapsulated silica nanoparticles.
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Figure 5.4, FT-IR spectra of the NH2 functionalized silica nanoparticles. The peak at 1655 cm-1
and 1550 cm-1 were assigned to the N-H bending from the amine group linked detection DNA.
5.3.3 Preparation of Streptavidin-Biotinylated Capture DNA Conjugates
The preparation of streptavidin-biotinylated DNA conjugates followed the previously
reported methods. 200 μL of 2.5 mg/ml of streptavidin was mixed with 50 mM of biotinylated
DNA probes (capture probe/control probe). The mixture was incubated on a shaker for 1 h. After
adding 500 μL PBS into the mixture, the solution was centrifuged in dialysis tube for 20 minutes
at 6000 rpm under 4°C. The above steps were repeated for 3 times to remove the unbound DNA.
The remaining solution in filter was diluted to 600 μL with PBS.
5.3.4 Preparation of Test Strip
The test strip consisted of four components: sample application pad, conjugate pad,
nitrocellulose (NC) membrane, and absorption pad. All components were made from paper
materials and they were laminated into a sheet of plastic pad orderly. The sample pad was made
from cellulose fiber (GFCP000800) and saturated with a Tris-HCl buffer (pH 8.0) containing
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0.23% of Triton X-100, 0.05 M of Tris-HCl and 0.15 M of NaCl. Then, the pad was dried at
37°C for 2 h and stored in desiccators at room temperature (RT). The test line and control line on
the NC membrane (HFB18004 and HFB 24004) were prepared by dispensing streptavidinbiotinylated capture probe and streptavidin-biotinylated control probe solutions respectively with
a home-made dispenser. The distance between the test and control lines was 3 mm. The
membrane was then dried at 37°C for 1 h and stored at 4°C in a dry state. The successful
functionalization of streptavidin-biotinylated DNA on the test line was verified through the peaks
at 1575 cm-1 and 1542 cm-1 of FT-IR spectra in Figure 5.5, which presents the N-H bending of
the biotin group. Finally, the sample pad, conjugate pad, NC membrane, and absorption pad were
assembled on a plastic adhesive backing (60 mm × 30 cm) (HF000MC100). Each part
overlapped 2 mm to ensure that the solution could migrate through the test strip during the assay.
Test strips with a 3-mm width were cut using a paper cutter. The detection DNA probe linked
NIRF nanoparticles were dropped on the conjugate pad prior to the test. The formation of the
NIRF test strip was exhibited in Figure 5.6a.
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Figure 5.5. FT-IR spectra of the capture DNA functionalized NC membrane. The peak at 1575
cm-1 and 1542 cm-1 were assigned to the N-H bending from the biotin group linked capture DNA
probe.

Figure 5.6. Schematic illustration of a) the formation of the paper-based NIRF test strip and b)
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miRNA-34 detection with the NIRF test strip; c) digital images of the portable fluorescent reader
and NIRF test strip in cassette.
5.4 ANALYTICAL CHARACTERIZATION
5.4.1 Operation Principle
The operation principle of the NIRF-PLFS for target circulating miRNA detection is shown
in Figure 5.6b. The overall mechanism of the detection process involves the reaction of (a) the
formation of NIRF linked detection DNA-miRNA complex on the conjugate pad; (b) the
complex from step (a) was captured on to the test line via the formation of a sandwiched
structure of NIRF/detection DNA-miRNA-capture DNA; (c) the formation of a complex of
NIRF/detection DNA-secondary DNA on control line. The schematic illustration of the above
mentioned steps are respectively shown in Figure 5.7. Since the presence of target miRNA
induces the formation of a fluorescent dye linked sandwich-structured complex onto the NIRF
test strip, consequently, the fluorescent signal is directly proportional to the quantity of target
miRNA. During a typical assay, a NIRF test strip was firstly loaded into a cassette (Figure 5.6c),
then 100 μL of sample solution was dropped into the sample window of the cassette. After that,
owing to capillary force, the solution migrated along with the test strip from sample pad to
conjugate pad, where the reaction between miRNA with detection DNA probe linked NIRF
nanoparticles occurred. Then the resulted complexes kept moving along with the test strip until
they reached the test line and captured by capture DNA through the formation of a sandwich
structure (NIRF/detection DNA-miRNA-capture DNA). The rest of NIRF/detection DNA
conjugates migrated over the test line and captured by the control line where the secondary DNA
probe was immobilized. After reaction, the test strip was analyzed by a cPoc fluorescent strip
reader, which is a portable handheld device (Figure 5.6c). During the data acquiring, the
fluorescent peak intensity was used for quantitative work since the peak intensity is in proportion
to the concentration of target miRNA.

76

Figure 5.7. Formations of complex of (NIRF/detection DNA-miRNA-capture DNA) and
(NIRF/detection DNA-control DNA) on test line and control line respectively.
5.4.2 Parameter Optimizations
The running buffer is a critical experimental component affecting the signal readout, which
plays a crucial role in increasing detection signal and reducing nonspecific adsorption of
fluorescent probes on test line. In the current study, TWEEN 20 was used as surfactant in
running buffer to control the flow rate and reduce the background fluorescent signal. As shown
in Figure 5.8a, with the increasing amount of TWEEN 20, the fluorescent S/N ratio rises
gradually and then tends to a constant value at 0.3%, which is chosen as the optimized TWEEN
20 amount. The reaction time is another important parameter of the NIRF test strip, which
improves the bounding stability of detection reagent and target miRNA with the capture DNA
immobilized test line. Meanwhile, increasing reaction time can help reduce background signal as
the nonspecific adsorbed fluorescent probe on test line can be washed away by the running
buffer. The reaction time was optimized from 1 to 50 min, and as shown in Figure 5.8b, the
optimal S/N is obtained from the reaction at 40 min.
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Figure 5.8. Experiment optimizations with NIRF test strips for miRNA measurements. a) Effect
of surfactant of TWEEN 20 amount in running buffer; B) effect of the reaction time; C) effect of
the volume of NIRF/detection DNA conjugate; D) effect of the dispensing times of the capture
DNA on test line on the S/N ratio of the NIRF based test strip.
The amounts of detection DNA-NIRF conjugate and capture DNA on test line can
substantially affect the signal intensity. From Figure 5.8c we can see that with the conjugate
volume increase, the S/N ratio increases because more NIRF nanoparticles are captured by test
line in the present of miRNA. When the volume of conjugate exceeds 7 μL, the S/N ratio
decreases owing to that the increased non-specific adsorption of NIRF nanoparticles on test line.
Therefore, 7 μL of NIRF conjugate is optimal. The capturing capacity of NIRF nanoparticles
onto test line is depended on the capturing reagent amount. In the current study, 3 times of
dispensing of capturing reagent onto test line was found to be the optimal and used in the
following experiment (Figure 5.8d).
5.4.3 Stability Comparison
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Figure 5.9. Stability comparison of different dyes: a) Cy7, b) Alexa 633 and c) Rhodamine 6G
encapsulated silica nanoparticles in buffer, 50% of plasma and 100% of plasma.
In order to demonstrate the advantages of NIRF in increasing the photostability and antiinterference capacity, the effect of biological matrices on the fluorescent intensity of the NIRF
and VisF dyes encapsulated silica nanoparticles was investigated. The results are exhibited in
Figure 5.9. The X axis of the figures presents the position of the nanoparticles on the test strip.
Figure 5.9a, b and c respectively describes the fluorescent spectra of NIRF (Cy7), VisF-1
(Alexa 633) and VisF-2 (Rhodamine 6G) encapsulated silica nanoparticles in the present of
buffer (green line with squares), 50% of blood plasma (orange line with spheres) and 100% of
blood plasma (pink line with triangles). The corresponding excitation/emission spectra of the
employed dyes are shown in Figure 5.10.

Figure 5.10. Excitation and emission spectra of the a) cyanine; b) Alexa 633 and c) Rhodamine
6G respectively. The information source of the spectra is from Lumiprobe, Life technologies and
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Fluka respectively.
From Figure 5.9a we can see that there is no manifest change in the fluorescent intensity
when NIRF nanoparticles were suspended even in 100% of blood plasma specimen in
comparison to that in running buffer. This is because that the wavelengths of the NIRF
nanoparticles fall within the biological window, which provides increased transparency toward
biological matrices. As a result, in that optical region, there is less absorbance, minimal
scattering and reduced background fluorescent interference, which endowing the NIRF
nanoparticles with favorable stability in biological matrices and, accordingly, offering accurate
measurement for bioanalysis. In contrast to the NIRF nanoparticles, the VisF-1 encapsulated
silica nanoparticles showed fluorescent intensity decreases by 23.6% and 37.8% (Figure 5.9b)
respectively in 50% and 100% of blood plasma. The results implied that there was great
scattering interference from biological matrix, which severely influence its luminance intensity.
In the case of VisF-2, the situation was even worse. Substantial signal decreases were observed
from the VisF-2 nanoparticles when they existed in the biological matrices (Figure 5.9c).
Moreover, the baselines of the fluorescent spectra were wavy and oscillating, which were
contributed to the background interference from test strip materials and surrounding environment,
leading to imprecise signal response and low detection sensitivity. Interestingly, compared with
VisF-2 nanoparticles (Figure 5.9c), VisF-1 nanoparticles (Figure 5.9b) possessed smooth and
flat spectrum baselines, indicating that the background interference played less effect on the
VisF-2 nanoparticles. This is because that the wavelengths of VisF-2 nanoparticles fall near the
left border of the NIR region, which endowed the nanoparticles with improved anti-interference
capacity towards the biological matrices and surrounding environment. The above findings
revealed that the NIRF played a vital role in elevating the photostability and avoiding the
background interference from surrounding environment, holding promises in direct bioanalysis.
5.4.4 Analytical Characterization
In order to evaluate the performances of the NIRF-PLFSs, sample solutions containing
different concentrations of miRNA-34 (ranging from 0 to 100 nM) were measured under the
optimal experimental conditions. As descripted in Figure 5.11a, the fluorescent response ((II0)/I0) linearly increases with the increasing of logarithm of target circulating miRNA
concentration, and the corresponding regression equation was y = 7.2x + 18.6 with a correlation
coefficient of 0.93. The detection limit of the NIRF-PLFS for target circulating miRNA-34 was
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found to be 20 pM, which was estimated based on three times of signal-to-noise ratio. A linear
detection range from 50 pM to 100 nM was obtained and was suitable for quantitative work. The
above results implied that the developed NIRF-PLFS were working properly and reliably. The
fluorescent signal stability was determined through measuring NIRF-PLFS with three
concentration levels of miRNA-34 (50 nM, 1 nM and 0 nM). Each measurement of miRNA was
repeated six times on six NIRF-PLFS. Results for the three concentration levels of miRNA
yielded a RSD respectively of 9.0%, 3.4% and 2.7%. The results exhibited outstanding
reproducibility, which clearly verified that the silica layer ameliorated the stability of the NIRF
encapsulated nanoparticles, thereby allowing reproducible fluorescent responses to be obtained
from different test strips constructed under the same condition.
In order to validate the anti-interference performance of the NIRF-PLFS in the present of
complex biological samples, various concentrations of miRNA was spiked with 50% of blood
plasma solutions. Then the resulted mixtures were examined by the NIRF-PLFSs. The test
results were described in Figure 5.11b. Compared with the data from Figure 5.11a, under the
same concentration of miRNA, there were no substantial signal decreases observed when the
measurements were carried out in 50% of blood plasma, which indicated that the complex
sample matrix exhibited very slight effect on the NIRF detection. As a result, a LOD of 50 pM of
miRNA was achieved when the NIRF-PLFSs were operated in 50% of blood plasma. A
calibration curve was obtained by plotting the response versus logarithm of miRNA
concentration, which was ranged from 0.1 nM to 100 nM.
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Figure 5.11. MiRNA-34 detection with various concentrations in buffer with a) NIRF, c) VisF-1
and e) VisF-2 nanoparticles incorporated test strips; and in 50% of plasma with b) NIRF, d) VisF1 and f) VisF-2 nanoparticles incorporated test strips. (I presents the fluorescent intensity in the
present of various concentrations of miRNA-34; while I0 presents the fluorescent intensity in the
absent of miRNA-34).
5.4.5 Performance Comparison
NIRF test strip

VisF-1 test strip

VisF-2 test strip

(Cy7)

(Alexa 633)

(Rhodamine 6G)

100 nM-50 pM

100 nM-50 pM

100 nM-0.1 nM

LOD

20 pM

5 pM

50 pM

50%

Linear

100 nM-0.1 nM

100 nM-0.5 nM

100 nM-10 nM

Plasma

Range
50 pM

100 pM

5000 pM

Buffer

Linear
Range

LOD
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Table 5.2. Comparisons of test results from VisF and NIRF test strips for miRNA detection in
buffer and in 50% of blood plasma samples.
To further verify the advanced anti-interference capacity of NIR nanoparticles, the
comparisons among the VisF-1, VisF-2 and the NIRF incorporated PLFSs were conducted
through detecting target miRNA in 50% of blood plasma specimens. In order to facilitate the
comparison, all of the synthesis procedures and tests conditions of the NIRF and the VisFs test
strips were kept same. The obtained calibration curves and the corresponding data including
LODs and linear ranges were presented and summarized respectively in Figure 5.11 and Table
5.2. From the data we can see that in running buffer, the LODs for target miRNA from the VisF2 and NIRF-PLFSs were at the same concentration level. But when the measurements were
carried out in 50% of blood plasma, the LOD from NIRF-PLFS was 100 times lower than that
from the VIF-2-PLFSs (5000 pM vs 50 pM). In addition, in comparison to the fluorescent
responses from VisF-2-PLFSs for measuring 10 nM of miRNA in running buffer, a five-time
decrease of fluorescent response was observed when the tests were conducted in 50% of blood
plasma samples (Figure 5.11b and f). The severe signal drops are attributed to substantial
scattering loss of the excitation and emission light in the biological matrix. In contrast, the
fluorescent responses from the NIRF-PLFSs were found to be very stable even for low
concentration detection of target miRNA in 50% of blood plasma samples. Moreover, the slope
of the calibration curve from the NIRF-PLFSs was comparable to that from the running buffer,
which demonstrated that the detection sensitivity of the NIRF-PLFS wasn’t affected significantly
when the system was operated in biological samples. Consequently, the LOD for miRNA on the
NIRF-PLFS was found to be 50 pM, which was at the same concentration level compared to that
from the running buffer.
5.5 CONCLUSION
In this work, we developed a strategy for the synthesis of novel NIRF dye encapsulated
silica nanoparticles through coating of commercial silica beads with NIRF dyes and a silica outer
layer. The silica coating layer enables numerous NIRF to be encapsulated into the nanoparticle,
leading to substantial fluorescent enhancement. Additionally, the silica layer can protect the dyes
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from the complex biological matrix. Moreover, the NIRF nanoparticles present advantages over
VisF nanomaterials in terms of improved anti-interference ability and minimized background
interference signal. As a result, the NIRF-PLFSs showed a two-order of magnitude improvement
in detection sensitivity for miRNA in 50% of blood plasma samples, which is expected to hold
promise as a POC tool in biological assays and other bio-applications.
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Chapter 6: AMPLIFICATION STRATEGY MODIFIED TEST STRIP IN
PLASMA TESTING
6.1 NUCLEASE-ASSISTED AMPLIFICATION TECHNIQUE
MicroRNAs (miRNAs) are a class of single-stranded non-coding RNA, which regulate gene
expression by either inhibition of translation or mRNA degradation.80 Studies have shown that
alterations in miRNA-expression play a significant effect on biological processes of disease
development and progression, including proliferation, differentiation and apoptosis.81 Thus,
miRNAs have become clinical promising biomarkers and have been explored in a variety of
studies. Accurate and sensitive measurement of miRNAs holds great significance for detecting
and predicting the resistance of different types of malignancies as well as for monitoring
treatment response.82 However, the major challenge of miRNA measurement is that the low
abundance of microRNAs but the high sequence homology within miRNA families in tissues,
cells and circulating system. Hence the standard approaches for miRNA measurements,
including Northern blotting and microarray are hindered by their intrinsic low sensitivity and
specificity limitations. The quantitative reverse transcription-polymerase chain reaction (qRTPCR) is a well-established gold standard method for miRNA measurements, which exhibits
dramatically improvement in detection sensitivity, leading to single molecule assay.83 However,
the short length of miRNAs requires the design of short primers and precise control of
temperature cycling for successful amplification, which decreases the efficiency of PCR and
increases the chances of nonspecific amplification. Moreover, the approaches depend on
laboratory-oriented sophisticated instruments, expert personnel and tedious operations, which
severely hamper their practical application, especially in remote and resource-limited and areas.
Recently, a variety of novel amplification strategies have been developed to improve the
detection sensitivity and adaptability for miRNA detection, including nanomaterial-based
miRNA detection84 and various kinds of nucleic acid amplification techniques75c, 85, including
rolling circle amplification (RCA),86 exponential isothermal amplification (EXPAR)87 and
nuclease-assisted amplifications (NAA).88 Nanomaterial-based amplification mainly depends on
the unique properties of nanomaterials, such as inherent high carrier capacity, and outstanding
conductivity and catalytic ability, offering the platform with eminent optical and electrochemical
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features.89 While NAA techniques primarily rely on an enzymatic process, which generates
thousands to millions of copies of a specific DNA segment. For instance, the RCA technique
enables the amplifications of a short DNA or RNA primer in the present of a circularized padlock
probe and the corresponding special DNA or RNA polymerases. RCA is a powerful tool to detect
DNA mutation, owing to the fact that even a single mismatch in the ligation junction does not
allow circularizing of the probe (Rolling circle amplification: a versatile tool for chemical
biology, materials science and medicine.90 In the case of EXPAR technique, one simple template
and two enzymes are required. The two enzymes are respectively utilized in nicking
endonuclease reaction and polymerase strand extension. EXPAR technique has gained increase
attention in amplifying of low-abundance miRNA due to its high sensitivity and good tolerance
to the inhibitory components in the clinical samples.91
Although the above mentioned techniques offer some advantages in miRNA amplification,
they have practical limitations in time, cost, and simplicity. Among the NAA techniques, the
duplex-specific nuclease (DSN) assisted signal amplification offers a rapid, convenient but
powerful alternative strategy for highly sensitive miRNA detection. It enables the linear signal
amplification without changing the quantity of the target miRNA.92 In addition, the DSNmediated signal amplification strategy owns unique advantages of high amplification efficiency,
isothermal nature, and no nonspecific priming. The mechanism of DSN assisted amplification
strategies are based on the cleavage of the single strand DNA probe only when it is in a DNARNA hybrid, while keeping the RNA intact. Then the target RNA acts as a template for a fresh
DNA probe and repeats the process of hybridization and cleavage, leading to signal
amplification.93 Various transducers have been integrated into DSN based sensors for achieving
ultra-sensitivity for miRNA measurements, including colorimetry,93c,
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fluorescence88b,
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and

electrochemistry.96 Although the procedures have been simplified compared with other NAA
techniques, most of the reported DSN based sensors still suffer from complicated nanofabrication
and multiple step operations, which cannot meet the demands of point-of-care (POC)
applications.
Paper-based lateral flow strips (PLFSs) are one of the best well-known POC tools, which
possess the advantages of user friendly operation, portability and low cost. PLFSs have been
employed in a variety of fields, such as environmental monitoring, food safety, and clinical
diagnosis for detecting various biomolecules and chemical contaminants. However, PLFSs
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rarely involves in detection of early-stage diseases, owing to the fact that the sensitivity and
accuracy of a PLFT are always sacrificed in order to simplify test procedures and accelerating
sample screening. In the current study, in order to realize high sensitivity measurement of
miRNA, the DSN assisted signal amplification strategy was introduced to modify PLFSs. The
developed DNS-PLFSs can sustain the properties of a POC tool, at the same time, realizing
ultrasensitive measurement of miRNA. In addition, near-infrared fluorescent NIRF (dylight 755)
encapsulated silica nanoparticles were employed as signal reporters, which can further amplify
signal response, meanwhile reduce the interference signal of the non-specific biomolecules from
human fluids. As a result, the proposed device allowed a quantitative evaluation of miRNA-34a
with a detection limit (LOD) of 0.1 pM in running buffers and a LOD of 0.5 pM in blood plasma
samples. The obtained LOD of miRNA-34a is below the cut-off value of that in the plasma
samples of stroke patients, exhibiting great potential as a POC miRNA quantification tool for use
in biomedical research and clinical diagnosis. Moreover, compared with other miRNA
amplification methods, the developed DSN-PLFS shows advantages in terms of simplicity, low
cost, fast response (within 40 min) and user-friendly properties.
6.2 MATERIALS AND METHODS
6.2.1 Reagents and Materials
N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and
tetraethyl orthosilicate (TEOS) were purchased from Sigma-Aldrich; HAuCl4, Na3PO4·12H2O,
Tween 20, Triton X-100, trisodium citrate, PBS (pH = 7.4), Bovine serum albumin (BSA),
sodium chloride, streptavidin were purchased from Sigma-Aldrich and used without further
purification. Sucrose was purchased from VWR. 3-Triethoxylsilylpropyl succinic anhydride
(TEPSA) was obtained from Gelest Inc. Silica nanosphere (60 nm) was purchased from
Nanocomposix, Inc. DyLight™ 755 NHS Ester was purchased from Thermo Scientific. Blood
plasma was purchased from US Biological Life Science (P4252-56 Plasma, Human, IgG Free).
Duplex-specific nuclease (DSN) kit (containing DSN enzyme, DSN storage buffer, 10X DSN
master buffer, 2X DSN stop solution and control template) was purchased from Evrogen. RNase
inhibitor was purchased from Sigma-Aldrich. Water glass distilled PCR Certified was purchased
from VWR.
Target miRNAs, detection probes and capture probes were purchased from Integrated DNA
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Technologies, Inc. (Coralville, IA) and have the following sequences:
Target miRNA-34a:
5’-UGG CAG UGU CUU AGC UGG UUG U -3’
miRNA sequence with two mismatches:
5’-UGU CUG UGU CUU AGC UGG UUG U -3’
Detection probe:
5’-/AmMC6/-GCG CGC GCA CAA CCA GCT AAG ACA CTG CCA-/Bio/-3’
Capture probe:
5’-/Biotin/GCG CGC GC-3’
Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), laminated cards
(HF000MC100), and nitrocellulose membranes (HFB18004 and HFB 24004) were purchased
from Millipore (Billerica, MA). E/D cPOC fluorescent readers (750 nm/755 nm) was purchased
from LRE Medical GmbH.
6.2.2 Instruments and Characterization
Fourier transform infrared (FT-IR) spectra were obtained with Thermo Nicolet 6700
spectrometer. A scanning electron microscope (JEOL-JSM-7600F) was used to image the
fluorescent dye encapsulated nanoparticles.

Figure 6.1. SEM images of a) commercial silica beads and b) synthesized NIRF nanoparticles.

6.2.3 Synthesis of Nanoparticles
The encapsulation of dyes was accomplished by coating of commercial silica nanospheres
with an outer layer containing fluorescent dyes. In brief, 50 μL of 100 μg/mL of fluorescent dye
was mixed with 50 μg/mL of commercial silica nanospheres in 10 mL of ethanol solution. The
obtained mixture was kept stirring for 20 min. Then 10 μL of TEOS and 10 uL of 28% ammonia
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hydroxide were added into the solution with 20 min intervals. All of the above reactions were
carried out under darkness. After overnight incubation, the reaction between TEOS and ammonia
hydroxide leads to the formation of a silica shell on the dye-nanoparticle surface. The resulting
nanoparticles were collected by washing and re-dispersion steps through centrifuging in ethanol
solution for several times. The final nanoparticles were re-suspended in 1 mL of ethanol solution
for future use. This encapsulation method guarantee the uniformity of the dye encapsulated silica
nanoparticles and has potential to permit the synthesis of dye encapsulated silica nanoparticles
with precisely tunable sizes through adjusting the amount of TEOS and ammonia hydroxide.
Particle sizes were determined by Nano Measurer. Figure 6.1a and b show the SEM images of
the commercial silica beads and the synthesized NIRF encapsulated silica nanoparticles
respectively. The average particle sizes of the commercial silica beads and the NIRF
nanoparticles were found to be 59.6 ± 2.2 nm and 64.5 ± 3.3 respectively. The increase in size
reveals that the thickness of the silica outer layer was at ~ 5 nm. The fluorescence emission
spectrum of the synthesized NIRF nanoparticles is presented in Figure 6.2. The wavelength of
the maximum fluorescence emission is at 769 nm.

Figure 6.2. Fluorescence emission spectrum of the synthesized NIRF nanoparticles.
6.2.4 Labeling detection DNA with Nanoparticles
The preparation detection DNA labeled with NIRF NPs followed the previously reported
method. The obtained 1 mL of NIRF NPs was mixed with 20 μL of TEPSA. The mixture
solution was incubated overnight to achieve carboxyl group-terminated NIRF NPs. The
successful conjugation of carboxyl-group onto the surface of NIRF NPs was confirmed by FT-IR
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spectra (Figure 6.3). After washing with ethanol and D.I. water for several times, the resulting
nanoparticles were re-suspended in 0.5 mL of the solution containing 50 mM NHS and 200 mM
EDC. After incubation for 2 h, the COOH group was activated. 50 μL of 20 μM of DNA (amine
group labeled detection DNA) solution was then added into the mixture. After overnight
incubation, the solution was washed with a buffer solution (PBS containing 0.1% of BSA) for
three times. The resulting nanoparticles were finally suspended in 200 μL of Eluent buffer (20
nM of Na3PO4·12H2O containing 5% BSA, 0.25% Tween 20, and 10% sucrose) and stored under
4 °C for future use. The successful conjugation of the detection DNA probe onto the NIRF NPs
was confirmed by the FT-IR spectra (Figure 6.4).

Figure 6.3. FT-IR spectra of the carboxyl-group labeled NIRF NPs. The peak at 1709 cm-1 peak
is assigned to the C=O stretching vibration in COOH of TEPSA.
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Figure 6.4. FT-IR spectra of the detection DNA probe functionalized NIRF NPs. The peaks at
1655 and 1541 cm-1: correspond to the N-H bending in the NH2 labeled DNA.
6.2.5. Labeling Biotinylated Detection DNA with Streptavidin
The biotin-lated detection DNA probe (50 mM) /NIRF NPs was mixed with 200 μL of 2.5
mg/ml of streptavidin. The mixture was incubated on a shaker for 1 h. The solution was
dispensed on the sample pad of the PLFS.
6.2.6 Preparation of Test Strip
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Figure 6.5. Schematic illustration of the DSN-PLFS.
Figure 6.5 exhibits the schematic illustration of the fabricated DSN-PLFS, which consists of
five components: a sample pad (reaction chamber), a thermoelectric controller, NC membrane, a
paper bridge and an absorption (wick) pad. All the components were mounted on a common
backing layer (typically an inert plastic, e.g., polyester). The sample pad was saturated with a
Tris-HCl buffer (pH 8.0) containing 0.23% Triton X-100 and 0.05 and 0.15 M NaCl. The pad
was then dried at 37 °C for 2 h and stored in a desiccator at room temperature (RT). Then, 5 μL
of NIRF NPs labeled detection DNA probe was dispensed on the samples pad of the PLFS. After
the sample pad was dried at 37 °C for 10 min, 0.25 U of DSN was loaded onto it and then the
sample pad was dried and stored at 4 °C under a dry condition. 0.5 μL of 1 mg/mL capture
antibodies was dropped onto the NC membrane to form a test dot. The membrane was then dried
and stored at 4 °C under a dry condition. Finally, the sample pad, NC membrane and the
absorption pad were successively assembled onto a plastic adhesive backing layer. The NC
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membrane and absorption pad were overlapped with 2 mm to ensure that the solution was able to
flow across the components. Each strip was cut to be 3 mm wide by a paper cutter (Swingline 12
in. ClassicCut Lite Trimmer). During the test, the PLFS was soaked into a tube containing 100
μL of sample solution with concentration of target miRNA. Then the tube was incubated in an
oven under 60 °C for 20 min. After reaction, a paper bridge (8 mm × 3 mm) was placed in the
gap between the sample pad the NC membrane, enabling the flow of the sample solution to
migrate to the detection area on the NC membrane. After 20 min reaction, the PLFS was
analyzed by a portable fluorescent reader. The fluorescent peak intensity was in proportion to the
concentration of target antigen, which was used for quantitative work

Figure 6.6. Schematic illustration of the signal amplification principle of the DSN-LFTS.

93

6.3 RESULTS AND DISCUSSION
6.3.1 Operation Principle
The procedure of signal amplification of a DSN-PLFS is illustrated in Figure 6.6. As shown
in the figure, single strand detection DNA probes labeled NIRF NPs are functionalized on the
sample pad. The sequence of the detection DNA probe is specifically designed based on the
sequences of the target miRNA and the capture DNA probe. The part II of the detection probe is
fully complementary with target miRNA; while the part I is complementary with capture DNA
probe on the test area. Upon the addition of target miRNA, it is hybridized with the part II of the
detection probe, leading to the formation of miRNA-detection DNA/NIRF NPs heteroduplex on
the sample pad. Owing to the present of DSN, the part II DNA probe in the heteroduplex is
immediately degrades, at the same time, the target miRNA and the remained part I DNA probe
linked NIRF NPs are released. Following the specific cleavage reaction, the released miRNA
subsequently hybridizes with the part II probe of the remaining detection DNA to repeat the
hybridization/cleavage cycle, leading to the concentration amplification of the NIRF NPs linked
DNA probes. The detailed illustration of this amplification procedure is presented in Figure 6.7.

Figure 6.6. Detailed illustration of the signal amplification principle of the DSN-LFTS.
After the amplification reaction, a paper bridge is placed between the sample pad and the NC
membrane to guide the liquid migration from the amplification chamber to the NC membrane,
where the capture DNA probe is functionalized. When the solution migrates to the test line, the
functionalized capture DNA on the test line can grab the complex of part I DNA probe-NIRF NP
through DNA complementary hybridization. At this moment, the NIRF NPs are accumulated on
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the test line and the captured amount is in proportion to the concentration of the target miRNA,
which can be employed for quantification work. In the absent of target miRNA, detection DNA
linked NIRF NPs cannot be released owing to the fact that DSN is only active towards with the
DNA inside of the DNA/RNA heteroduplex but inactive towards single-stranded DNA and RNA.
The PLFS is then analyzed by a portable handheld fluorescent strip reader, which has been
exhibited in Figure 5.6c.
6.3.2 Optimizations

Figure 6.8. Optimization of the experiment conditions for DSN-PLFS. a) Effect of the DSN
amount on the fluorescent signals of the PLFSs, b) effect of the NIRF NPs/detection DNA probe
on the S/N ratio, c) effect of the volume of capture DNA probe on the S/N ratio.
In order to optimize the sensor performance, the DSN-PLFS was employed to measure 10 pM
of miRNA. Since the DSN significantly influences the hybridization/cleavage reactions and the
released amount of NIRF NPs, therefore, the amount of DNS in this amplification system was
studied. As shown in Figure 6.8a, the signal intensity of the fluorescent peak increases with the
growing amount of DSN until it reaches 0.25 U. Further increase in the DSN amount shows little
effect on the increase of the peak intensity. Therefore, the optimal amount of DNS was 0.25 U.
The amount of the detection DNA-NIRF NPs and the concentration of capture DNA probe on
the test line are another two important parameters, because both of them affect the ability of
DSN-PLFS to capture the NIRF NPs on the test line, which significantly affects the signal
intensity and detection sensitivity. As shown in Figure 6.8b, c, the optimal amount of the
detection DNA-NIRF NPs was 5 μL, and 5 μL of the capture DNA probe was the best.
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Figure 6.9. Optimization of the experiment conditions for DSN-PLFS. a) Effect of the on the
reaction temperature of the DSN-PLFSs, b) effect of the reaction time on the S/N ratio of the
DSN-PLFSs.
The optimal temperature of DSN-PLFS was determined tuning reaction temperature varying
from 25 ºC to 70 ºC. Under the conditions employed, the highest S/N ratio was observed at 55 °C.
Further increases in temperature were accompanied by a signal decrease (Figure 6.9a). This
might reflect enzyme denaturation. We also evaluated the effect of incubation time of enzyme
amplification reaction on S/N ratio (Figure 6.9b). We found that increases in incubation time
were accompanied by increases in S/N ratio until incubation time reached 25 min. After 25 min,
S/N ratios were remained constant. Therefore, the optimal incubation time of the enzyme
amplification reaction was 25 min
6.3.3 Performance in Running Buffer
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Figure 6.10. Peak intensity of the fluorescent signal obtained from the DSN-PLFS in running
buffer with different concentrations of miRNA (ranging from 0 to 100 nM).
In order to further evaluate the performances of the DSN-PLFS, sample solutions containing
different concentrations of miRNA-34 (ranging from 0 to 100 nM) were measured under optimal
experimental conditions. During a typical test, a DSN-PLFS was soaked into a tube which
contains 100 μL of sample solution. After the amplification reaction in the oven for 20 min and
the reaction of the capturing NIRF NPS on the test line for another 20 min, the fluorescent
response of the DSN-PLFS was recorded. As descripted in Figure 6.10, the fluorescent intensity
increases with the increasing of miRNA concentration, which indicates that the DSN-PLFS is
working properly. The calibration curve showed a linear range from 175 fM to 100 nM. The
detection limit of the DSN-PLFS for target miRNA was found to be 150 fM, which was
estimated based on three times of signal-to-noise ratio. Compared with the sensitivity of NIRFPLFS in Chapter 5, an improvement in sensitivity of three-orders of magnetite was obtained by
the developed DSN-PLFS for miRNA measurement in running buffer samples.
6.3.4 Performance in 50% of Blood Plasma
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Figure 6.11. The fluorescent intensities of the DSN-PLFS test zones in the presence of 500 fM
of miRNA-34, 500 fM of interference miRNA and 0 fM of miRNA in running buffer and 50% of
plasma.
Anti-interference ability is an important parameter to evaluate a biosensor. Before the test
was conducted in real plasma samples, selectivity test was carried out by employing miRNA
molecule with two mismatches of bases towards target miRNA-34. As demonstrated in Figure
6.11, compared with the target signals, signals from the interference tests are comparable with
the signals generated from control experiments and can be negligible, indicating that the
developed DSN-PLFS exhibits good selectivity towards interference miRNA molecules. The
intrinsic advantages can merit miRNA detection in complex real samples.
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Figure 6.12. Peak intensity of the fluorescent signal obtained from the DSN-PLFS in 50% of
blood plasma with different concentrations of miRNA (ranging from 0 to 100 nM).
The performance of the DSN-PLFS was then studied in the complex human fluids. 50% of
plasma sample solutions containing different concentrations of miRNA-34 (ranging from 0 to
100 nM) were measured under optimal experimental conditions. After the reactions, the
fluorescent response of the DSN-PLFS was recorded by a portable fluorescent reader. As
descripted in Figure 6.12, the fluorescent intensity increases with the increasing of miRNA
concentration. The fluoresce cent peak intensity (y) versus the miRNA-34 concentration (x) was
fitted as y = 311.2x + 1198.4 with the relative coefficient (R2) of 0.95, showing a linear detection
range from 500 fM to 100 nM, achieving a LOD of 300 fM. The LOD was estimated according
to three times of signal-to-noise ratio. Compared with the sensitivity of NIRF-PLFS in Chapter
5, an improvement in sensitivity of two orders of magnitude was obtained by the developed
DSN-PLFS for miRNA measurement in running buffer samples. Our experimental results show
the DSN-PLFS developed in the present work can work for miRNA-34 detection in blood
plasma.
6.3.5 Measurement of miRNA-34 Biomarker in Clinical Blood Plasma Samples
The calibrated DSN-PLFS was employed to measure the miRNA-34 biomarker level in
clinical blood plasma taken from stroke patients. Figure 6.13 shows the miRNA-34
concentrations in six clinical blood plasma samples measured by the DSN-PLFS. The results
indicated that the developed DSN-PLFS can work properly in clinical patient samples and can
meet the demands for measuring trace amount of miRNA biomarkers directly from clinical
samples. Compared with clinical standard PCR approach, the developed DSN-PLFS exhibits
advantages in simplicity, shorter reaction time, low cost and used friendly.
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Figure 6.13. miRNA-34 concentrations in clinical blood plasma samples, which were measured
by DSN-PLFS.
6.4 CONCLUSION
The DSN-PLFS was developed for ultrasensitive measurement of stroke biomarker
microRNA-34 in blood plasma samples. DSN assisted amplification technique was employed to
modify the PLFS for improving the sensor performance. After signal amplification, the DSNPLFS can amplify fluorescent response, leading to an improvement in detection sensitivity with
two-orders of magnitude. The obtained LOD was below the cut-off value that presents in the
blood samples of stroke patients. Moreover, the DSN-PLFS shows advantages over the standard
PCR approach, including low cost, portability, short operation time, and simple operation
procedure. These merits endow the DSN-PLFS with great potential to be employed as a POC
tool for monitoring the miRNA biomarkers in biological samples. The DSN-PLFS was
successfully employed for detection of miRNA-34a in clinical blood plasma samples. Obviously,
the DSN-PLFS has advantages over the standard PCR approach, including low cost, portability
and short operation time. These merits endow the DSN-PLFS with great potential to be
employed as a POC tool for monitoring the miRNA biomarkers in real-world samples.
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Chapter 7 CONCLUSION AND OUTLOOK
This dissertation summarized the background, recent advances and obstacles of PLFS devices
for disease biomarker detections. In order to solve the problems and fill the gaps between the
PLFSs and the practical POC devices, several strategies have been proposed:
1) Two parallel routes of ultrasensitive techniques: SERS and NIR fluorescence techniques
have been employed in PLFSs to build proof-of-concept sensors and improve detection
sensitivity;
2) Synthesized SERS and NIRF nanomaterials with silica coating layers to protect the
nanomaterials from the interference from the surrounding environment, leading to the
improvement in anti-interference capacity;
3) Tuned the SERS and NIRF nanomaterials to the near-infrared window to reduce the
interference signals from surrounding environment and biological matrices;
4) Fabricated blood plasma separation unit (PSU) to reduce the interference from the RBCs
from whole blood samples;
5) Integrated SERS-PLFS with plasmonic chip to form 3D confined plamonic field for further
improving signal intensity and sensitivity;
6) Modified PLFSs with duplex specific nuclease (DSN)-mediated signal amplification
strategy for improving detection sensitivity.
As a result, the developed PLFSs in this dissertation can realize accurate and direct
measurement of biomarkers from clinical samples, showing great advantages as a practical POC
device. Despite the progress that has been achieved in this dissertation, there still exist some
issues to be solved. (i) Although the proposed PLFS has realized disease biomarker detection
from clinical samples, it is still difficult to employ PLFS to indicate a specific disease if only one
biomarker is detected during one trial. Therefore, a high-throughput PLFS which enables
multiple biomarker measurements can substantially improve the diagnostic specificity. (ii)
Compared with paper materials, the employed blood plasma filtration membrane in this
dissertation is relatively more expensive. In order to further decrease the cost of the device, other
less-expensive materials, such as porous polymers or general filter paper might provide
alternative choices for filtrating plasma from whole blood samples. (iii) During one PLFS test, at
least 100 μL of aqueous solutions or clinical samples is required, which is not applicable for the
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applications of miniscule amounts of samples and reagents. The future innovative research is
expected to introduce microfluidic technique with PLFS through fabricating microfluidic
channels on PLFS surfaces through wax-printing technique to solve this problem.
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